

(12) STANDARD PATENT APPLICATION (11) Application No. AU 2022282057 A9
(19) AUSTRALIAN PATENT OFFICE

(54) Title
NOVEL DUAL HELPER PLASMID

(51) International Patent Classification(s)
C12N 15/86 (2006.01) **C12N 15/63** (2006.01)

(21) Application No: **2022282057** (22) Date of Filing: **2022.05.27**

(87) WIPO No: **WO22/250491**

(30) Priority Data

(31) Number	(32) Date	(33) Country
10-2021-0068364	2021.05.27	KR
17/750,241	2022.05.20	US

(43) Publication Date: **2022.12.01**

(48) Corrigenda Journal Date: **2024.01.25**

(71) Applicant(s)
NEURACLE GENETICS INC.

(72) Inventor(s)
HAN, Joo Seok;KONG, Hoon Young;HWANG, Yoon Hyung

(74) Agent / Attorney
PHILLIPS ORMONDE FITZPATRICK, PO Box 323, COLLINS STREET WEST, VIC, 8007, AU

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau


(43) International Publication Date
01 December 2022 (01.12.2022)



(10) International Publication Number
WO 2022/250491 A1

- (51) International Patent Classification:
C12N 15/86 (2006.01) C12N 15/63 (2006.01)
- (21) International Application Number: PCT/KR2022/007553
- (22) International Filing Date: 27 May 2022 (27.05.2022)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
10-2021-0068364 27 May 2021 (27.05.2021) KR
17/750,241 20 May 2022 (20.05.2022) US
- (71) Applicant: NEURACLE GENETICS INC. [KR/KR];
145 Anam-ro, Seongbuk-gu, Seoul 02841 (KR).
- (72) Inventors: HAN, Joo Seok; 227dong-1403ho, 119
Gireum-ro, Seongbuk-gu, Seoul 02714 (KR). KONG,
Hoon Young; 106dong-602ho, 253 Cheonjung-ro, Gang-
dong-gu, Seoul 05300 (KR). HWANG, Yoon Hyung;
- (74) Agent: CHUNG HYUN PATENT & LAW FIRM; Bethel
Bldg. 8F., 23, Dongsan-ro, Seocho-gu, Seoul 06779 (KR).
- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.
- (84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: NOVEL DUAL HELPER PLASMID



(57) Abstract: The present disclosure relates to a dual helper plasmid for producing a recombinant adeno-associated virus. A double transfection method using the dual helper plasmid of the present disclosure is advantageous over the triple transfection method typically used for production of adeno-associated virus in terms of 1) increased chance of cotransfection, 2) increased productivity of recombinant adeno-associated virus, 3) reduction in cost and time of plasmid production and purification, etc., and thus can be usefully utilized for effective production of a gene therapy agent.

[Continued on next page]



WO 2022/250491 A1

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

Description

Title of Invention: Novel Dual Helper Plasmid

Technical Field

- [1] The present disclosure relates to a novel dual helper plasmid for producing a recombinant AAV for gene delivery.

Background Art

- [2] Adeno-associated virus (AAV) is a single-stranded DNA virus which belongs to helper-dependent parvoviruses requiring help from adenovirus, etc. for proliferation. It is a non-pathogenic virus having a genome size of about 4.7 kbp and does not induce cell-mediated immune response. The target of infection varies widely depending on serotypes and the virus can deliver genes to non-dividing and dividing cells. In particular, the expression of the genes delivered by the AAV is continued for a long time *in vivo* [1-3].
- [3] Typically, recombinant adeno-associated virus is produced by triple transfection of host cells (*e.g.*, HEK293 cells) [4]. It requires 1) an AAV construct plasmid having a gene expression cassette flanked by ITRs (inverted terminal repeats), 2) a "Rep-Cap plasmid" which provides Rep proteins necessary for the replication of the adeno-associated virus genome and capsid proteins that constitute virus particles and, finally, 3) a "helper plasmid" which provides the proteins (E2a, E4) and RNAs (VA RNAs) of adenovirus that help the life cycle of adeno-associated virus. Adeno-associated virus is produced when these three types of plasmids are transfected into HEK293 cells, etc. that provide the *E1* and *E3* genes of adenovirus [5].
- [4] The recombinant adeno-associated virus vector is produced only in the cells transfected with all of the above-mentioned three plasmids. If two plasmids are combined as one for double transfection, the chance of co-transfection will increase and, consequently, the production yield of the recombinant adeno-associated virus will be increased [6, 7]. In addition, since the number of the plasmids required to produce the recombinant adeno-associated virus is decreased from three to two, the time and cost required for producing and purifying the plasmids will be saved, too [8].
- [5] The recombinant adeno-associated virus vector cannot be replicated *in vivo* because it does not retain the *rep* and *cap* genes and does not have adenovirus-derived genes [9].
- [6] However, because the relative location of *rep*, *cap*, *E2*, *E4* and *VA RNA* genes in the plasmid varies depending on how the Rep-Cap plasmid and the helper plasmid are combined to prepare a dual helper plasmid, the expression of each gene is affected differently and it is very difficult to expect the effect on productivity.

- [7] Accordingly, an engineered dual helper plasmid designed to increase the chance of transfection of a recombinant adeno-associated virus vector and the productivity of a recombinant adeno-associated virus therethrough and, at the same time, reduce the time and cost of the production and purification of a plasmid, and a method for preparing the same are keenly needed.
- [8] [References of the Related Art]
- [9] [Non-Patent Documents]
- [10] 1. *BioDrugs*. 2017. 31(4): 317-334. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. M. F. Naso, B. Tomkowicz, W. L. Perry 3rd, W. R. Strohl.
- [11] 2. *Expert Opin. Drug Saf.* 2002. 1(1): 79-91. Safety of Adeno-Associated Viral gene Therapy Vectors: A Current Evaluation. P. E. Monahan, K. Jooss, M. S. Sands.
- [12] 3. *Gene Ther.* 1996. 3(8): 658-68. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. C. K. Conrad, S. S. Allen, S. A. Afione, T. C. Reynolds, S. E. Beck, M. Fee-Maki, X. Barraza-Ortiz, R. Adams, F. B. Askin, B. J. Carter, W. B. Guggino, T. R. Flotte.
- [13] 4. *J. Virology*. 1998. 72(3): 2224-2232. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. X. Xiao, J. Li, R. J. Samulski.
- [14] 5. *Viruses*. 2010. 2(8): 1681-1703. Adenoviral producer cells. I. Kovesdi and S. J. Hedley.
- [15] 6. *Hum. Gene Ther.* 1998. 9(18): 2745-2760. Novel tools for production and purification of recombinant adeno-associated virus vectors. D. Grimm, A. Kern, K. Rittner, J. A. Kleinschmidt.
- [16] 7. *Mol. Ther.* 2003. 7(6): 839-850. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. D. Grimm, M. A. Kay, J. A. Kleinschmidt.
- [17] 8. *Biores. Open Access*. 2020. 9(1): 219-228. Two-Plasmid Packaging System for Recombinant Adeno-Associated Virus. Q. Tang, A. M. Keeler, S. Zhang, Q. Su, Z. Lyu, Y. Cheng, G. Gao, T. R. Flotte.
- [18] 9. *Hum. Gene Ther.* 2017. 28(11): 1075-1086 Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution. D. Grimm, H. Buening.

Disclosure of Invention

Solution to Problem

- [19] Provided herein is a dual helper plasmid comprising an *E2a* gene, *E4* gene, *VA RNA* gene, and *rep-cap* gene, wherein the *E2a*, *E4*, and the *VA RNA* genes are linked sequentially, and wherein the *rep-cap* gene is located between the 5'-terminal of the *E2a* gene and the 3'-terminal of the *VA RNA* gene in a clockwise direction (from 5' to 3').

[20] Provided herein is a dual helper plasmid comprising an *E2a* gene, *E4* gene, *VA RNA* gene, and *rep-cap* gene, wherein the *E2a*, *E4*, and the *VA RNA* genes are linked sequentially, and wherein the *rep-cap* gene is located between the 5'-terminal of the *E2a* gene and the 3'-terminal of the *VA RNA* gene in a counterclockwise direction (from 3' to 5').

[21] Provided herein is a dual helper plasmid comprising a regulatory component, wherein the regulatory component comprises (from 5' to 3'):

[22] (i) an *E2a* gene, which comprises the sequence set forth in SEQ ID NO: 34;

[23] (ii) an *E4* gene, which comprises the sequence set forth in SEQ ID NO: 35;

[24] (iii) a *VA RNA* gene, which comprises the sequence set forth in SEQ ID NO: 36;

[25] (iv) a *cap* gene, which comprises the sequence set forth in SEQ ID NO: 30; and

[26] (v) a *rep* gene, which comprises the sequence set forth in SEQ ID NO: 29.

[27] Provided herein is a dual helper plasmid comprising a regulatory component, wherein the regulatory component comprises (from 5' to 3'):

[28] (i) an *E2a* gene, which comprises the sequence set forth in SEQ ID NO: 34;

[29] (ii) an *E4* gene, which comprises the sequence set forth in SEQ ID NO: 35;

[30] (iii) a *VA RNA* gene, which comprises the sequence set forth in SEQ ID NO: 36;

[31] (iv) a *cap* gene, which comprises the sequence set forth in SEQ ID NO: 31; and

[32] (v) a *rep* gene, which comprises the sequence set forth in SEQ ID NO: 29.

[33] Provided herein is a dual helper plasmid comprising a regulatory component, wherein the regulatory component comprises (from 5' to 3'):

[34] (i) an *E2a* gene, which comprises the sequence set forth in SEQ ID NO: 34;

[35] (ii) an *E4* gene, which comprises the sequence set forth in SEQ ID NO: 35;

[36] (iii) a *VA RNA* gene, which comprises the sequence set forth in SEQ ID NO: 36;

[37] (iv) a *cap* gene, which comprises the sequence set forth in SEQ ID NO: 32; and

[38] (v) a *rep* gene, which comprises the sequence set forth in SEQ ID NO: 29.

[39] Provided herein is a dual helper plasmid comprising a regulatory component, wherein the regulatory component comprises (from 5' to 3'):

[40] (i) an *E2a* gene, which comprises the sequence set forth in SEQ ID NO: 34;

[41] (ii) an *E4* gene, which comprises the sequence set forth in SEQ ID NO: 35;

[42] (iii) a *VA RNA* gene, which comprises the sequence set forth in SEQ ID NO: 36;

[43] (iv) a *cap* gene, which comprises the sequence set forth in SEQ ID NO: 33; and

[44] (v) a *rep* gene, which comprises the sequence set forth in SEQ ID NO: 29.

[45] Provided herein is a composition comprising any of the dual helper plasmid of the present disclosure.

[46] Provided herein is a cell comprising any of the dual helper plasmid or the composition of the present disclosure.

[47] Provided herein is a method of producing a recombinant AAV, comprising

modifying a cell to comprise a first plasmid and a second plasmid, wherein the first plasmid is any of the dual helper plasmid of the present disclosure, and wherein the second plasmid comprises a transgene.

[48] Provided herein is a method of increasing the yield of recombinant AAV during production, comprising modifying a cell to comprise a first plasmid and a second plasmid, wherein the first plasmid is any of the dual helper plasmid of the present disclosure and the second plasmid comprises a transgene, and wherein the amount of recombinant AAV produced after the modifying is increased compared to the corresponding amount produced with a reference method.

[49] Provided herein is a recombinant AAV produced by any of the method of the present disclosure.

[50] Provided herein is a pharmaceutical formulation comprising any of the recombinant AAV of the present disclosure, and a pharmaceutically acceptable excipient.

[51] Provided herein is a method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject any of the recombinant AAV or the pharmaceutical formulation of the present disclosure.

[52] Provided herein is an use of any of the recombinant AAV or the pharmaceutical formulation of the present disclosure in the manufacture of a medicament for treating a disease or disorder in a subject in need thereof.

Brief Description of Drawings

[53] FIGS. 1A-1F show the cleavage maps of pHelper-NG and Helper-In-One constructs (pHION8 series) for producing adeno-associated virus vector serotype 8 (AAV8) prepared by the inventors of the present disclosure. FIG. 1A schematically shows a pHelper-NG construct for triple transfection, which includes the *E2a*, *E4* gene and *VA RNA* genes of adenovirus serotype 5. FIGS. 1B-1F schematically show five Helper-In-One-NG plasmid (pHION8) constructs, which are dual helper plasmids prepared by inserting *rep2-cap8* gene fragments into different regions of the pHelper-NG construct. FIGS. 1B and 1C schematically show a pHION8-BF construct prepared by cloning a *rep2-cap8* construct in a forward direction (clockwise direction, 5' -> 3') using the BamHI site present between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene (FIG. 1B) and a pHION8-BR construct prepared by cloning in a reverse direction (counterclockwise direction, 3' -> 5') (FIG. 1C). FIGS. 1D and 1E schematically show a pHION8-NF construct prepared by cloning a *rep2-cap8* construct in a forward direction using the NotI site present at the beginning portion of the *E4* gene (FIG. 1D) and a pHION8-NR construct prepared by cloning in a reverse direction (FIG. 1E). FIG. 1F schematically shows a pHION8-AF construct prepared by cloning a *rep2-cap8* construct in a forward direction using the AsiSI site

present between the beginning portion of the *VA RNA* gene and the ending portion of the *E4* gene.

[54] FIG. 2 shows the cleavage map of a pHNG2 construct, which is a dual helper plasmid for producing adeno-associated virus vector serotype 2 (AAV2). The pHNG2 construct was prepared by inserting a *rep2-cap2* gene fragment in a forward direction using the BamHI site present between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene in a pHelper-NG plasmid.

[55] FIG. 3 shows the cleavage map of a pHNG9 construct, which is a dual helper plasmid for producing adeno-associated virus vector serotype 9 (AAV9). The pHNG9 construct was prepared by cloning a *rep2-cap9* gene fragment in a forward direction using the BamHI site present between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene for double transfection.

[56] FIG. 4 shows the cleavage map of a pHNG5K construct, which is a dual helper plasmid for producing adeno-associated virus vector serotype 5 (AAV5). The pHNG5K construct was prepared by cloning a *rep2-cap5* gene fragment in a forward direction using the BamHI site present between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene for double transfection.

[57] FIGS. 5A and 5B show the cleavage maps of pHNG and pHNGR constructs. FIG. 5A shows a *rep-cap* gene fragment inserted in a forward direction between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene, and FIG. 5B shows the *rep-cap* gene fragment inserted in a reverse direction.

[58] FIG. 6 shows a result of observing the effect of double transfection (Double) using pHION8 series on the increase or decrease of AAV8 production in adhesion cells (HEK293) as compared to triple transfection (Triple).

[59] FIG. 7 shows a result of observing the effect of double transfection (Double) using pHION8 series on the increase or decrease of AAV8 production in suspension cells (Expi293) as compared to triple transfection (Triple).

[60] FIG. 8 shows a result of observing the effect of double transfection (Double) using pHNG2 on the increase of AAV2 production in adhesion cells (HEK293) as compared to triple transfection (Triple).

[61] FIG. 9 shows a result of observing the effect of double transfection (Double) using pHNG9 on the increase of AAV9 production in adhesion cells (HEK293) as compared to triple transfection (Triple).

[62] FIG. 10 shows a result of observing the effect of double transfection (Double) using pHNG5K on the increase of AAV5 production in adhesion cells (HEK293) as compared to triple transfection (Triple).

[63] FIG. 11 shows that AAV8s produced by triple transfection (Triple) or by double transfection (Double) using Helper-In-One constructs show comparable cell

transduction efficiency.

[64] FIG. 12 shows that AAV2s produced by triple transfection (Triple) or by double transfection (Double) using a pHNG2 construct show comparable cell transduction efficiency.

[65] FIG. 13 shows that AAV9s produced by triple transfection (Triple) or by double transfection (Double) using a pHNG9 construct show comparable cell transduction efficiency.

Mode for the Invention

[66] The present disclosure is generally directed to compositions and methods for producing recombinant AAVs, and the use of such rAAVs to treat a disease or disorder. As described herein, the dual helper plasmids of the present disclosure comprise multiple genes (*e.g.*, *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene). Applicant has identified that by arranging the multiple genes in certain configurations, the yield or productivity can be increased or decreased during recombinant AAV production. Additional aspects of the present disclosure are provided throughout the present application.

[67]

I. Definitions

[68] ***I. Definitions***

[69] Throughout this disclosure, the term "a" or "an" entity refers to one or more of that entity; for example, "a polypeptide," is understood to represent one or more polypeptides. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.

[70] Furthermore, "and/or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and/or" as used in a phrase such as "A and/or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Likewise, the term "and/or" as used in a phrase such as "A, B, and/or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[71] The term "at least" prior to a number or series of numbers is understood to include the number adjacent to the term "at least," and all subsequent numbers or integers that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, "at least 18 nucleotides of a 21-nucleotide nucleic acid molecule" means that 18, 19, 20, or 21 nucleotides have the indicated property. When at least is present before a series of numbers or a range, it is understood that "at least" can modify each of the numbers in the series or range. "At least" is also not limited to integers (*e.g.*, "at least 5%" includes

5.0%, 5.1%, 5.18% without consideration of the number of significant figures.

- [72] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of" and/or "consisting essentially of" are also provided.
- [73] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.
- [74] Units, prefixes, and symbols are denoted in their Systeme International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, amino acid sequences are written left to right in amino to carboxy orientation. The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.
- [75] The term "about" is used herein to mean approximately, roughly, around, or in the regions of. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" can modify a numerical value above and below the stated value by a variance of, e.g., 10 percent, up or down (higher or lower).
- [76] As used herein, the term "adeno-associated virus" (AAV), includes but is not limited to, AAV type 1, AAV type 2, AAV type 3 (including types 3A and 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, AAV type 11, AAV type 12, AAV type 13, AAVrh.74, snake AAV, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, goat AAV, shrimp AAV, those AAV serotypes and clades disclosed by Gao et al. (*J. Virol.* 78:6381 (2004)) and Moris et al. (*Virol.* 33:375 (2004)), and any other AAV now known or later discovered. *See, e.g.*, FIELDS et al. VIROLOGY, volume 2, chapter 69 (4th ed., Lippincott-Raven Publishers). In some aspects, an "AAV" includes a derivative of a known AAV. In some aspects, an "AAV" includes a modified or an artificial AAV.
- [77] The terms "administration," "administering," and grammatical variants thereof refer to introducing a composition (e.g., a recombinant AAV delivery vector produced using the dual helper plasmids of the present disclosure) into a subject via a pharmaceutically acceptable route. The introduction of a composition into a subject is by any suitable

route, including intratumorally, orally, pulmonarily, intranasally, parenterally (intravenously, intra-arterially, intramuscularly, intraperitoneally, or subcutaneously), rectally, intralymphatically, intrathecally, periocularly or topically. Administration includes self-administration and the administration by another. A suitable route of administration allows the composition or the agent to perform its intended function. For example, if a suitable route is intravenous, the composition is administered by introducing the composition or agent into a vein of the subject.

[78] As used herein, the term "**antibiotic resistance gene**" refers to a gene inserted to a plasmid in order to confer drug resistance so that a microorganism can survive even after exposure to an antibiotic. As described herein, in some aspects, an antibiotic resistance gene can be introduced into a plasmid (*e.g.*, dual helper plasmid) to screen cells having the desired plasmid through cloning. Non-limiting examples of antibiotic resistance genes that are useful for the present disclosure include ampicillin, kanamycin, chloramphenicol, gentamycin, streptomycin, tetracycline, erythromycin, vancomycin, penicillin, spectinomycin, chloramphenicol, sulfadiazine, and trimethoprim resistance genes

[79] As further described herein, the dual helper plasmids of the present disclosure comprise *rep* gene and *cap* gene which are present with the dual helper plasmids in certain orientation/configuration. In some aspects, the *rep* and *cap* genes are in a "**clockwise direction**," "**forward direction**," or "**5' -> 3'**" (*e.g.*, as shown in FIG. 5A), which means that the *rep-cap* gene is inserted or included in a clockwise direction or in a direction from the site where replication begins (5') to the site where replication ends (3'). In some aspects, the *rep* and *cap* genes are in a "**counterclockwise direction**," "**reverse direction**" or "**3' -> 5'**" (*e.g.*, as shown in FIG. 5B) means that the *rep-cap* gene is inserted or included in a counterclockwise direction or in a direction from the site where replication ends (3') to the site where replication begins (5').

[80] As used herein, the term "**rep gene**" refers to a gene which encodes one or more open reading frame (ORF), wherein the ORF encodes AAV Rep protein or a mutant or derivative thereof. The AAV Rep protein (or a mutant or derivative thereof) is involved in AAV genome replication and/or AAV genome packaging, and a wild-type *rep* gene encodes the four Rep proteins Rep78, Rep68, Rep52 and Rep40. Unless indicated otherwise, the term "*rep* gene" includes a wild-type *rep* gene, a derivative thereof, and an artificial *rep* gene having an equivalent function. In some aspects, the *rep* gene may be a *rep2* gene derived from adeno-associated virus serotype 2 (AAV2). In some aspects, the *rep2* gene comprises the nucleic acid sequence set forth in SEQ ID NO 29.

[81] As used herein, the term "*cap* gene" refers to a gene which encodes one or more open reading frame (ORF), wherein the ORF encodes AAV Cap structural protein, or a

mutant or derivative thereof. Four proteins are translated from the *cap* gene. Among them, VP1, VP2 and VP3 proteins are structural proteins constituting AAV particles, and assembly-activating protein (AAP) promotes the formation (assembly) of AAV particles by the structural proteins. Unless indicated otherwise, the term "*cap* gene" includes a wild-type *cap* gene, a derivative thereof and an artificial *cap* gene having an equivalent function. In some aspects, the *cap* gene is a *cap* gene derived from adeno-associated virus serotype 2 (AAV2; *cap2*), serotype 5 (AAV5; *cap5*), serotype 8 (AAV8; *cap8*) or serotype 9 (AAV9; *cap9*). In some aspects, the *cap* gene comprises the nucleic acid sequence set forth in SEQ ID NO 30 (*cap2*), SEQ ID NO 31 (*cap5*), SEQ ID NO 32 (*cap8*) or SEQ ID NO 33 (*cap9*).

[82] As used herein, the term "***E2a* gene**" refers to a gene encoding the protein E2a of adenovirus, which regulates the promoter of AAV, helps AAV genome replication and is involved in increased capsid protein production through splicing of Rep mRNA and enhanced stability of capsid mRNA. Unless indicated otherwise, the term "*E2a* gene" includes a wild-type *E2a* gene, a derivative thereof and an artificial *E2a* gene having an equivalent function. In a specific exemplary embodiment of the present disclosure, the *E2a* gene is an *E2a* gene derived from adenovirus serotype 5 (Ad5). In some aspects, the *E2a* gene comprises the nucleic acid sequence set forth in SEQ ID NO 34.

[83] As used herein, the term "***E4* gene**" refers to a gene encoding the protein E4 of adenovirus, which is involved in the second-strand synthesis of the AAV genome in the life cycle of AAV and helps AAV genome replication by inhibiting the formation of the MRN (Mre11-Rad50-Nbs1) complex, which is responsible for the intracellular mechanism that inhibits AAV genome replication. Unless indicated otherwise, the term "*E4* gene" includes a wild-type *E4* gene, a derivative thereof and an artificial *E4* gene having an equivalent function. In some aspects, the *E4* gene is an *E4* gene derived from adenovirus serotype 5 (Ad5). In some aspects, the *E4* gene comprises the nucleic acid sequence set forth in SEQ ID NO 35.

[84] As used herein, the term "***VA RNA(s)* gene**" or "***VA RNA(s)* region**" refers to a VA region that produces VA RNA, which increases the stability of AAV capsid mRNA, improves the efficiency of translation and helps preventing the degradation of the Rep52 protein. Unless indicated otherwise, the term "*VA RNA* gene" includes a wild-type *VA RNA* gene, a derivative thereof and an artificial *VA RNA* gene having an equivalent function. In some aspects, the *VA RNA* gene is a *VA RNA* gene derived from adenovirus serotype 5 (Ad5). In some aspects, the *VA RNA* gene comprises the nucleic acid sequence set forth in SEQ ID NO 36.

[85] As used herein, the term "conserved" refers to nucleotides or amino acid residues of a polynucleotide sequence or polypeptide sequence, respectively, that are those that occur unaltered in the same position of two or more sequences being compared. Nu-

cleotides or amino acids that are relatively conserved are those that are conserved amongst more related sequences than nucleotides or amino acids appearing elsewhere in the sequences.

[86] As used herein, the term "**control element**" refers to a nucleic acid sequence that regulate (*e.g.*, increase or decrease) the expression of an operably linked nucleic acid (*e.g.*, transgene). Non-limiting examples of suitable control elements are provided elsewhere in the present disclosure.

[87] In some aspects, two or more sequences are said to be "completely conserved" or "identical" if they are 100% identical to one another. In some aspects, two or more sequences are said to be "highly conserved" if they are at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to one another. In some aspects, two or more sequences are said to be "highly conserved" if they are about 70% identical, about 80% identical, about 90% identical, about 95%, about 98%, or about 99% identical to one another. In some aspects, two or more sequences are said to be "conserved" if they are at least 30% identical, at least 40% identical, at least 50% identical, at least 60% identical, at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to one another. In some aspects, two or more sequences are said to be "conserved" if they are about 30% identical, about 40% identical, about 50% identical, about 60% identical, about 70% identical, about 80% identical, about 90% identical, about 95% identical, about 98% identical, or about 99% identical to one another. Conservation of sequence can apply to the entire length of a polynucleotide or polypeptide or can apply to a portion, region or feature thereof.

[88] As used herein, the term "enhancer" refers to a segment of DNA which contains sequences capable of providing enhanced transcription and in some instances can function independent of their orientation relative to another control sequence. An enhancer can function cooperatively or additively with promoters and/or other enhancer elements.

[89] The terms "excipient" and "carrier" are used interchangeably and refer to an inert substance added to a pharmaceutical composition to further facilitate administration of a compound, *e.g.*, a recombinant AAV delivery vector comprising a transgene and produced using the dual helper plasmids provided herein.

[90] The term "exon" refers to a defined section of nucleic acid that encodes for a protein, or a nucleic acid sequence that is represented in the mature form of an RNA molecule after either portions of a pre-processed (or precursor) RNA have been removed by splicing. The mature RNA molecule can be a messenger RNA (mRNA) or a functional form of a non-coding RNA, such as rRNA or tRNA.

[91] The term "expression," as used herein, refers to a process by which a polynucleotide produces a gene product, *e.g.*, RNA or a polypeptide. It includes, without limitation,

transcription of the polynucleotide into messenger RNA (mRNA), and the translation of mRNA into a polypeptide. Expression produces a "gene product" or "encoded protein." As used herein, a gene product can be, e.g., a nucleic acid, such as an RNA produced by transcription of a gene. As used herein, a gene product can be either a nucleic acid or a polypeptide which is translated from a transcript. Gene products described herein further include nucleic acids with post transcriptional modifications, e.g., polyadenylation or splicing, or polypeptides with post translational modifications, e.g., phosphorylation, methylation, glycosylation, the addition of lipids, association with other protein subunits, or proteolytic cleavage.

[92] As used herein, the term "identity" refers to the overall monomer conservation between polymeric molecules, e.g., between polynucleotide molecules. The term "identical" without any additional qualifiers, e.g., polynucleotide A is identical to polynucleotide B, implies the polynucleotide sequences are 100% identical (100% sequence identity). Describing two sequences as, e.g., "70% identical," is equivalent to describing them as having, e.g., "70% sequence identity."

[93] Calculation of the percent identity of two polypeptide or polynucleotide sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second polypeptide or polynucleotide sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain aspects, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. The amino acids at corresponding amino acid positions, or bases in the case of polynucleotides, are then compared.

[94] When a position in the first sequence is occupied by the same amino acid or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm.

[95] Suitable software programs that can be used to align different sequences (e.g., polynucleotide sequences) are available from various sources. One suitable program to determine percent sequence identity is *bl2seq*, part of the BLAST suite of program available from the U.S. government's National Center for Biotechnology Information BLAST web site (blast.ncbi.nlm.nih.gov). *Bl2seq* performs a comparison between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to

compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other suitable programs are, e.g., Needle, Stretcher, Water, or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk/Tools/psa.

[96] Sequence alignments can be conducted using methods known in the art such as MAFFT, Clustal (ClustalW, Clustal X or Clustal Omega), MUSCLE, etc.

[97] Different regions within a single polynucleotide or polypeptide target sequence that aligns with a polynucleotide or polypeptide reference sequence can each have their own percent sequence identity. It is noted that the percent sequence identity value is rounded to the nearest tenth. For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to 80.1, while 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded up to 80.2. It also is noted that the length value will always be an integer.

[98] In some aspects, the percentage identity (%ID) of a first amino acid sequence (or nucleic acid sequence) to a second amino acid sequence (or nucleic acid sequence) is calculated as $\%ID = 100 \times (Y/Z)$, where Y is the number of amino acid residues (or nucleobases) scored as identical matches in the alignment of the first and second sequences (as aligned by visual inspection or a particular sequence alignment program) and Z is the total number of residues in the second sequence. If the length of a first sequence is longer than the second sequence, the percent identity of the first sequence to the second sequence will be higher than the percent identity of the second sequence to the first sequence.

[99] One skilled in the art will appreciate that the generation of a sequence alignment for the calculation of a percent sequence identity is not limited to binary sequence-sequence comparisons exclusively driven by primary sequence data. It will also be appreciated that sequence alignments can be generated by integrating sequence data with data from heterogeneous sources such as structural data (e.g., crystallographic protein structures), functional data (e.g., location of mutations), or phylogenetic data. A suitable program that integrates heterogeneous data to generate a multiple sequence alignment is T-Coffee, available at www.tcoffee.org, and alternatively available, e.g., from the EBI. It will also be appreciated that the final alignment used to calculate percent sequence identity can be curated either automatically or manually.

[100]

[101] As used herein, the terms "isolated," "purified," "extracted," and grammatical variants thereof are used interchangeably and refer to the state of a preparation of desired composition of the present disclosure, e.g., a polynucleotide comprising a transgene and an untranslated nucleic acid sequence, that has undergone one or more processes of purification. In some aspects, isolating or purifying as used herein is the process of removing, partially removing (e.g., a fraction) a composition of the present

disclosure, e.g., a polynucleotide described herein from a sample containing contaminants.

[102] The term "linked," as used herein, refers to a first amino acid sequence or polynucleotide sequence covalently or non-covalently joined to a second amino acid sequence or polynucleotide sequence, respectively. The first amino acid or polynucleotide sequence can be directly joined or juxtaposed to the second amino acid or polynucleotide sequence or alternatively an intervening sequence can covalently join the first sequence to the second sequence. The term "linked" means not only a fusion of a first polynucleotide sequence to a second polynucleotide sequence at the 5'-end or the 3'-end, but also includes insertion of the whole first polynucleotide sequence (or the second polynucleotide sequence) into any two nucleotides in the second polynucleotide sequence (or the first polynucleotide sequence, respectively). The first polynucleotide sequence can be linked to a second polynucleotide sequence by a phosphodiester bond or a linker. The linker can be, e.g., a polynucleotide.

[103] The terms "miRNA," "miR," and "microRNA" are used interchangeably and refer to a microRNA molecule found in eukaryotes that is involved in RNA-based gene regulation. The term will be used to refer to the single-stranded RNA molecule processed from a precursor. In some aspects, the term "antisense oligomers" can also be used to describe the microRNA molecules of the present disclosure. Names of miRNAs and their sequences related to the present disclosure are provided herein. MicroRNAs recognize and bind to target mRNAs through imperfect base pairing leading to destabilization or translational inhibition of the target mRNA and thereby downregulate target gene expression. Conversely, targeting miRNAs via molecules comprising a miRNA binding site (generally a molecule comprising a sequence complementary to the seed region of the miRNA) can reduce or inhibit the miRNA-induced translational inhibition leading to an upregulation of the target gene.

[104] "Nucleic acid," "nucleic acid molecule," "nucleotide sequence," "polynucleotide," and grammatical variants thereof are used interchangeably and refer to a sequence of nucleotides connected by phosphodiester linkages. Polynucleotides are presented herein in the direction from the 5' to the 3' direction. A polynucleotide of the present disclosure can be a deoxyribonucleic acid (DNA) molecule or acid (RNA) molecule. Nucleotide bases are indicated herein by a single letter code: adenine (A), guanine (G), thymine (T), cytosine (C), inosine (I) and uracil (U).

[105] As used herein, the term "operatively linked" or "operably linked" means that DNA sequences to be linked are located adjacent to each other to perform a desired function. For instance, a promoter is operatively linked to a coding region if the promoter helps initiate transcription of the coding sequence (e.g., transgene). As long as this functional relationship is maintained, the promoter needs not be contiguous with the coding

region.

[106] The terms "pharmaceutically acceptable carrier," "pharmaceutically acceptable excipient," and grammatical variations thereof, encompass any of the agents approved by a regulatory agency of the U.S. Federal government or listed in the U.S. Pharmacopeia for use in animals, including humans, as well as any carrier or diluent that does not cause the production of undesirable physiological effects to a degree that prohibits administration of the composition to a subject and does not abrogate the biological activity and properties of the administered compound. Included are excipients and carriers that are useful in preparing a pharmaceutical composition and are generally safe, non-toxic, and desirable.

[107] As used herein, the term "pharmaceutical composition" refers to one or more of the compositions described herein (e.g., polynucleotides, vectors, cells, and/or recombinant viruses) mixed or intermingled with, or suspended in one or more other chemical components, such as pharmaceutically acceptable carriers and excipients.

[108] As used herein, the terms "promoter" and "promoter sequence" are interchangeable and refer to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. Promoters can be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters can direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental or physiological conditions. Promoters that cause a gene to be expressed in most cell types at most times are commonly referred to as "constitutive promoters." Promoters that cause a gene to be expressed in a specific cell type are commonly referred to as "cell-specific promoters" or "tissue-specific promoters." Promoters that cause a gene to be expressed at a specific stage of development or cell differentiation are commonly referred to as "developmentally-specific promoters" or "cell differentiation-specific promoters." Promoters that are induced and cause a gene to be expressed following exposure or treatment of the cell with an agent, biological molecule, chemical, ligand, light, or the like that induces the promoter are commonly referred to as "inducible promoters" or "regulatable promoters." It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths can have identical promoter activity.

[109] The promoter sequence is typically bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site

(conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. In some aspects, a promoter that can be used with the present disclosure includes a tissue specific promoter.

[110] As used herein, the term "gene regulatory region" or "regulatory region" refers to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding region, and which influence the transcription, RNA processing, stability, or translation of the associated coding region. Regulatory regions can include promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing sites, effector binding sites, or stem-loop structures. If a coding region is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

[111] In some aspects, a nucleic acid composition provided herein (*e.g.*, expression construct) can include a promoter and/or other expression (*e.g.*, transcription) control elements operably associated with one or more coding regions. In an operable association a coding region for a gene product is associated with one or more regulatory regions in such a way as to place expression of the gene product under the influence or control of the regulatory region(s). For example, a coding region and a promoter are "operably associated" if induction of promoter function results in the transcription of mRNA encoding the gene product encoded by the coding region, and if the nature of the linkage between the promoter and the coding region does not interfere with the ability of the promoter to direct the expression of the gene product or interfere with the ability of the DNA template to be transcribed. Other expression control elements, besides a promoter, for example enhancers, operators, repressors, and transcription termination signals, can also be operably associated with a coding region to direct gene product expression.

[112] As used herein, the term "**transgene**" refers to one or more polynucleotide or polynucleotide region encoded into a recombinant expression construct, an expression product of the polynucleotide or polynucleotide region, or a polynucleotide or modulatory (or regulatory) nucleic acid encoding a polypeptide or polypeptides. As further described elsewhere in the present disclosure, in In some aspects, the transgene can be a nucleotide sequence encoding a therapeutic peptide for a particular disease, which is desired to be expressed continuously in the body of a subject or a patient. In some aspects, the term "**operatively linked**" or "**operably linked**" means that the DNA sequences to be linked are contiguous so as to perform their desired functions. For example, if a specific promoter helps the initiation of the transcription of a coding sequence (*e.g.*, a transgene), the promoter may be operatively linked to the coding

region. The promoter and the coding region do not need to be contiguous as long as this functional relationship is maintained.

- [113] In the present disclosure, the term "vector" or "construct" refers to a construct that can insert a nucleic acid or a gene and, specifically, includes a vector that can insert a nucleic acid sequence for introduction into a cell capable of replicating the nucleic acid sequence. The nucleic acid sequence may be exogenous or heterologous. The nucleic acid sequence may be a transgene. The construct may be a plasmid, a cosmid or a virus (e.g., AAV), although not being limited thereto. Those skilled in the art can construct the vector or construct using standard recombinant techniques (Maniatis, et al., *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1988; and Ausubel et al., In: *Current Protocols in Molecular Biology*, John, Wiley & Sons, Inc., NY, 1994).
- [114] In the present disclosure, the term "expression vector" or "expression construct" refers to a vector or a construct including a nucleotide sequence which encodes at least a portion of a transcribed gene product. In some cases, the transcribed RNA molecule is translated into a protein, a polypeptide or a peptide. The expression construct may include various control elements. In addition to a regulatory sequence that regulates transcription and translation, the vector or expression vector may further include a nucleotide sequence that provides another function.
- [115] As used herein, the term "subject" refers to an individual to which the AAV (produced using the methods provided herein) or a composition comprising such an AAV is administered. Non-limiting examples include humans, domestic animals (e.g., dogs, cats and the like), farm animals (e.g., cows, sheep, pigs, horses and the like), and laboratory animals (e.g., monkey, rats, mice, rabbits, guinea pigs and the like) for whom diagnosis, treatment, or therapy is desired, particularly humans. The methods described herein are applicable to both human therapy and veterinary applications.
- [116] As used herein, the phrase "subject in need thereof" includes subjects, such as mammalian subjects, that would benefit from administration of composition described herein.
- [117] As used herein, the term "therapeutically effective amount" is the amount of reagent or pharmaceutical compound comprising a composition of the present disclosure (e.g., polynucleotide comprising a transgene and an untranslated nucleic acid sequence) that is sufficient to produce a desired therapeutic effect, pharmacologic and/or physiologic effect on a subject in need thereof. A therapeutically effective amount can be a "prophylactically effective amount" as prophylaxis can be considered therapy.
- [118] As used herein, the term "transgene" refers to at least one polynucleotide or polynucleotide region encoded in a recombinant expression construct or an expression product of the polynucleotide or polynucleotide region, a polynucleotide encoding a

polypeptide or multi-polypeptide or a modulatory or regulatory nucleic acid. In some aspects, the transgene can be heterologous to the cell (i.e., not naturally expressed in the cell) in which it is inserted (or transduced).

- [119] The terms "treat," "treatment," or "treating," as used herein refers to, e.g., the reduction in severity of a disease or condition; the reduction in the duration of a disease course; the amelioration or elimination of one or more symptoms associated with a disease or condition; the provision of beneficial effects to a subject with a disease or condition, without necessarily curing the disease or condition. The term also includes prophylaxis or prevention of a disease or condition or its symptoms thereof.
- [120] The term "upstream" refers to a nucleotide sequence that is located 5' to a reference nucleotide sequence.
- [121] As used herein, the term "vector" or "construct" refers to any vehicle into which a nucleic acid or a gene can be inserted, such as delivery vehicles into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated. The nucleic acid sequence which can be inserted into a vector can be exogenous or heterologous. The nucleic acid sequence can be a transgene. Examples of constructs include, but are not limited to, plasmids, cosmids, and viruses (e.g., AAVs). Those skilled in the art can construct the vector or construct through standard recombinant techniques (Maniatis, et al., *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1988; and Ausubel et al., In: *Current Protocols in Molecular Biology*, John, Wiley & Sons, Inc, NY, 1994, etc.). As used herein, the term "expression vector" or "expression construct" refers to a vector or construct including a nucleotide sequence coding for at least a portion of a gene product to be transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide or peptide. Expression constructs can include various control elements. In addition to regulatory sequences that govern transcription and translation, vectors and expression vectors can include nucleotide sequence that serve other functions as well.
- [122] Vectors can be engineered to encode selectable markers or reporters that provide for the selection or identification of cells that have incorporated the vector. Expression of selectable markers or reporters allows identification and/or selection of host cells that incorporate and express other coding regions contained on the vector. Examples of selectable marker genes known and used in the art include: genes providing resistance to ampicillin, streptomycin, gentamycin, kanamycin, hygromycin, bialaphos herbicide, sulfonamide, and the like; and genes that are used as phenotypic markers, i.e., anthocyanin regulatory genes, isopentanyl transferase gene, and the like. Examples of reporters known and used in the art include: luciferase (Luc), green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), β -galactosidase (LacZ), β -

glucuronidase (Gus), and the like. Selectable markers can also be considered to be reporters.

[123] **II. Dual Helper Plasmids**

[124] II.A. *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene

[125] Some aspects of the present disclosure is directed to dual helper plasmids. As demonstrated herein, such dual helper plasmids can be particularly useful in producing a recombinant adeno-associated virus (AAV) (*e.g.*, comprising a transgene encoding a protein of interest).

[126] Adeno-associated virus (AAV) is a single-stranded DNA virus and a helper-dependent human parvovirus. It has a genome size of about 4.7 kbp. The N-terminal of the genome encodes the *rep* gene which is involved in viral replication and viral gene expression, and the C-terminal encodes the *cap* gene which encodes the capsid protein of the virus. Inverted terminal repeats (ITRs) of about 145 bases are inserted at both terminals. The 145-bp ITRs (inverted terminal repeats) having a T-shaped structure function as a replication origin during the replication of the viral genome and serve as a primary packaging signal. The ITRs are the only *cis*-active base sequences required for making a recombinant AAV construct. Although they have enhancer activity in the presence of the Rep protein, they have minimal activity in the absence of the Rep protein. Thus, an expression construct is prepared with appropriate enhancer, promoter, pA, etc. when cloning a transgene into the recombinant AAV construct (RJ Samulski and N Muzyczka, *Annu. Rev. Virolo.* 2014. 1:427-451). Four proteins are translated from the *rep* gene. Their names depict their molecular weights: *rep78*, *rep68*, *rep52* and *rep40*. They play an important role in AAV DNA replication. Four proteins are translated from the *cap* gene. Among them, VP1, VP2 and VP3 proteins are structural proteins constituting AAV particles, and assembly-activating protein (AAP) promotes the formation (assembly) of AAV particles by the structural proteins. For the adeno-associated virus to be replicated effectively, proteins and RNAs derived from a helper virus such as adenovirus or herpes simplex virus are necessary (Muzyczka N. *Curr Top Microbiol Immunol* 158, 97-129, 1992).

[127] As used herein, "**dual helper plasmid**" refers to a plasmid that is capable of providing two or more of the requirements for producing AAV in a cell. To produce a recombinant AAV vector comprising a transgene, the following components must be provided to the host cells: (1) transgene, (2) rep and cap proteins, and (3) E2a, E4, and VA RNA proteins. As described elsewhere in the present disclosure, with traditional methods, the different requirements are provided to the cells using three different plasmids (*i.e.*, ① AAV construct plasmid comprising the transgene flanked by ITRs, ② Rep-Cap plasmid, and ③ helper plasmid).

[128] As is apparent from the present disclosure, in some aspects, a dual helper plasmid

described herein provides requirements (2) and (3) described above. For instance, in some aspects, the dual helper plasmid comprises a *rep* gene, *cap* gene, *E2a* gene, *E4* gene, and *VA RNA* gene.

[129] As demonstrated herein, dual helper plasmids described herein not only comprise the above-described genes but the genes are also arranged in certain configurations within the plasmid. For instance, in some aspects, the *E2a* gene, *E4* gene, and the *VA RNA* gene are linked sequentially within the dual helper plasmid, and the *rep* gene and the *cap* gene (referred to herein collectively as "***rep-cap* gene**") are between the 5'-terminal of the *E2a* gene and the 3'-terminal of the *VA RNA* gene sequentially in a clockwise direction (from 5' to 3'). More specifically, in some aspects, the 5'-terminal of the *rep-cap* gene is linked to the 5'-terminal of the *E2a* gene, and wherein the 3'-terminal of the *rep-cap* gene is linked to the 3'-terminal of the *VA RNA* gene. A non-limiting example of such a dual helper plasmid is illustrated in FIG. 5A.

[130] In some aspects, the *E2a* gene, *E4* gene, and the *VA RNA* gene are linked sequentially, and the *rep-cap* gene is between the 5'-terminal of the *E2a* gene and the 3'-terminal of the *VA RNA* gene in a counterclockwise direction (from 3' to 5'). More specifically, in some aspects, the 3'-terminal of the *rep-cap* gene is linked to the 5'-terminal of the *E2a* gene, and wherein the 5'-terminal of the *rep-cap* gene is linked to the 3'-terminal of the *VA RNA* gene. A non-limiting example of such a dual helper plasmid is illustrated in FIG. 5B.

[131] As is apparent from the present disclosure, in some aspects, each of the *E2a* gene, *E4* gene, and *VA RNA* gene described above are derived from Adenovirus. In some aspects, the *cap* gene and the *rep* gene are derived from the same AAV serotype. For instance, in some aspects, both the *cap* gene and the *rep* gene are derived from AAV2 (see, e.g., pUC-R2C2 construct described in Example 1-4). In some aspects, the *cap* gene and the *rep* gene are derived from AAVs having different serotype. For instance, as demonstrated herein, in some aspects, the *cap* gene is derived from AAV8 (*cap8* or a fragment thereof) and the *rep* gene is derived from AAV2 (*rep2* or a fragment thereof) (see, e.g., pUC-R2C8 construct described in Example 1-2). In some aspects, the *cap* gene is derived from AAV9 (*cap9* or a fragment thereof) and the *rep* gene is derived from AAV2 (*rep2* or a fragment thereof) (see, e.g., pUC-R2C9 construct described in Example 1-6). In some aspects, the *cap* gene is derived from AAV5 (*cap5* or a fragment thereof) and the *rep* gene is derived from AAV2 (*rep2* or a fragment thereof) (see, e.g., pUC-R2C5 construct described in Example 1-7).

[132] Non-limiting examples of types or serotypes of the AAV that can be used in the present disclosure include AAVrh.10 (AAVrh10), AAV-DJ (AAVDJ), AAV-DJ8 (AAVDJ8), AAV1, AAV2, AAV2G9, AAV3, AAV3a, AAV3b, AAV3-3, AAV4, AAV4-4, AAV5, AAV6, AAV6.1, AAV6.2, AAV6.1.2, AAV7, AAV7.2, AAV8,

AAV9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84, AAV9.9, AAV10, AAV11, AAV 12, AAV16.3, AAV24.1, AAV27.3, AAV42.12, AAV42-1b, AAV42-2, AAV42-3a, AAV42-3b, AAV42-4, AAV42-5a, AAV42-5b, AAV42-6b, AAV42-8, AAV42-10, AAV42-11, AAV42-12, AAV42-13, AAV42-15, AAV42-aa, AAV43-1, AAV43-12, AAV43-20, AAV43-21, AAV43-23, AAV43-25, AAV43-5, AAV44.1, AAV44.2, AAV44.5, AAV223.1, AAV223.2, AAV223.4, AAV223.5, AAV223.6, AAV223.7, AAV1-7/rh.48, AAV1-8/rh.49, AAV2- 15/rh.62, AAV2-3/rh.61, AAV2-4/rh.50, AAV2-5/rh.51, AAV3.1/hu.6, AAV3.1/hu.9, AAV3-9/rh.52, AAV3-11/rh.53, AAV4-8/r1 1.64, AAV4-9/rh.54, AAV4-19/rh.55, AAV5-3/rh.57, AAV5-22/rh.58, AAV7.3/hu.7, AAV16.8/hu.10, AAV16.12/hu.11, AAV29.3/bb.1, AAV29.5/bb.2, AAV106.1/hu.37, AAV114.3/hu.40, AAV127.2/hu.41, AAV127.5/hu.42, AAV128.3/hu.44, AAV130.4/hu.48, AAV145.1/hu.53, AAV145.5/hu.54, AAV145.6/hu.55, AAV161.10/hu.60, AAV161.6/hu.61, AAV33.12/hu.17, AAV33.4/hu. 15, AAV33.8/hu. 16, AAV52/hu. 19, AAV52.1/hu.20, AAV58.2/hu.25, AAVA3.3, AAV A3.4, AAVA3.5, AAV A3.7, AAVC1, AAVC2, AAVC5, AAVF3, AAVF5, AAVH2, AAVrh.72, AAVhu.8, AAVrh.68, AAVrh.70, AAVpi.1, AAVpi.3, AAVpi.2, AAVrh.60, AAVrh.44, AAVrh.65, AAVrh.55, AAVrh.47, AAVrh.69, AAVrh.45, AAVrh.59, AAVhu.12, AAVH6, AAVLK03, AAVH-1/hu.1, AAVH-5/hu.3, AAVLG-10/rh.40, AAVLG-4/rh.38, AAVLG-9/hu.39, AAVN721-8/rh.43, AAVCh.5, AAVCh.5R1, AAVcy.2, AAVcy.3, AAVcy.4, AAVcy.5, AAVCy.5R1, AAVCy.5R2, AAVCy.5R3, AAVCy.5R4, AAVcy.6, AAVhu.1, AAVhu.2, AAVhu.3, AAVhu.4, AAVhu.5, AAVhu.6, AAVhu.7, AAVhu.9, AAVhu.10, AAVhu.11, AAVhu.13, AAVhu.15, AAVhu.16, AAVhu.17, AAVhu.18, AAVhu.20, AAVhu.21, AAVhu.22, AAVhu.23.2, AAVhu.24, AAVhu.25, AAVhu.27, AAVhu.28, AAVhu.29, AAVhu.29R, AAVhu.31, AAVhu.32, AAVhu.34, AAVhu.35, AAVhu.37, AAVhu.39, AAVhu.40, AAVhu.41, AAVhu.42, AAVhu.43, AAVhu.44, AAVhu.44R1, AAVhu.44R2, AAVhu.44R3, AAVhu.45, AAVhu.46, AAVhu.47, AAVhu.48, AAVhu.48R1, AAVhu.48R2, AAVhu.48R3, AAVhu.49, AAVhu.51, AAVhu.52, AAVhu.54, AAVhu.55, AAVhu.56, AAVhu.57, AAVhu.58, AAVhu.60, AAVhu.61, AAVhu.63, AAVhu.64, AAVhu.66, AAVhu.67, AAVhu.14/9, AAVhu.t 19, AAVrh.2, AAVrh.2R, AAVrh.8, AAVrh.8R, AAVrh.12, AAVrh.13, AAVrh.13R, AAVrh.14, AAVrh.17, AAVrh.18, AAVrh.19, AAVrh.20, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36, AAVrh.37, AAVrh.37R2, AAVrh.38, AAVrh.39, AAVrh.40, AAVrh.46, AAVrh.48, AAVrh.48.1, AAVrh.48.1.2, AAVrh.48.2, AAVrh.49, AAVrh.51, AAVrh.52, AAVrh.53, AAVrh.54, AAVrh.56, AAVrh.57, AAVrh.58, AAVrh.61, AAVrh.64, AAVrh.64R1, AAVrh.64R2, AAVrh.67, AAVrh.73, AAVrh.74,

AAVrh8R, AAVrh8R A586R mutant, AAVrh8R R533A mutant, AAV, BAAV, caprine AAV, bovine AAV, AAVhE1.1, AAVhE1.5, AAVhE1.14, AAVhE1.8, AAVhE1.16, AAVhE1.18, AAVhE1.35, AAVhE1.7, AAVhE1.36, AAVhE2.29, AAVhE2.4, AAVhE2.16, AAVhE2.30, AAVhE2.31, AAVhE2.36, AAVhE1.23, AAVhE3.1, AAV2.5T, AAV-PAEC, AAV-LK01, AAV-LK02, AAV-LK03, AAV-LK04, AAV-LK05, AAV-LK06, AAV-LK07, AAV-LK08, AAV-LK09, AAV-LK10, AAV-LK11, AAV-LK12, AAV-LK13, AAV-LK14, AAV-LK15, AAV-LK16, AAV-LK17, AAV-LK18, AAV-LK19, AAV-PAEC2, AAV-PAEC4, AAV-PAEC6, AAV-PAEC7, AAV-PAEC 8, AAV-PAEC 11, AAV-PAEC 12, AAV-2-pre-miRNA-101, AAV-8h, AAV-8b, AAV-h, AAV-b, AAV SM 10-2, AAV Shuffle 100-1, AAV Shuffle 100-3, AAV Shuffle 100-7, AAV Shuffle 10-2, AAV Shuffle 10-6, AAV Shuffle 10-8, AAV Shuffle 100-2, AAV SM 10-1, AAV SM 10-8, AAV SM 100-3, AAV SM 100-10, B P61 AAV, B P62 AAV, B P63 AAV, AAVrh.50, AAVrh.43, AAVrh.62, AAVrh.48, AAVhu.19, AAVhu.11, AAVhu.53, AAV4-8/rh.64, AAVLG-9/hu.39, AAV54.5/hu.23, AAV54.2/hu.22, AAV54.7/hu.24, AAV54.1/hu.21, AAV54.4R/hu.27, AAV46.2/hu.28, AAV46.6/hu.29, AAV128.1/hu.43, true type AAV (ttAAV), UPENN AAV10, Japanese AAV10 serotype, and any combinations thereof.

- [133] In some aspects, the serotype of the adeno-associated virus useful for the present disclosure comprises AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh10, or a combination thereof. Accordingly, in some aspects, one or more of the multiple genes of a dual helper plasmid are derived from AAV1. For instance, in some aspects, the *rep* gene is derived from AAV1. In some aspects, the *cap* gene is derived from AAV1. In some aspects, both the *rep* gene and the *cap* gene are derived from AAV1. In some aspects, one or more of the multiple genes of a dual helper plasmid are derived from AAV2. For instance, in some aspects, the *rep* gene is derived from AAV2. In some aspects, the *cap* gene is derived from AAV2. In some aspects, both the *rep* gene and the *cap* gene are derived from AAV2. In some aspects, one or more of the multiple genes of a dual helper plasmid are derived from AAV3. For instance, in some aspects, the *rep* gene is derived from AAV3. In some aspects, the *cap* gene is derived from AAV3. In some aspects, both the *rep* gene and the *cap* gene are derived from AAV3. In some aspects, one or more of the multiple genes of a dual helper plasmid are derived from AAV4. For instance, in some aspects, the *rep* gene is derived from AAV4. In some aspects, the *cap* gene is derived from AAV4. In some aspects, both the *rep* gene and the *cap* gene are derived from AAV4. In some aspects, one or more of the multiple genes of a dual helper plasmid are derived from AAV5. For instance, in some aspects, the *rep* gene is derived from AAV5. In some aspects, the *cap* gene is derived from AAV5. In some aspects, both the *rep* gene and the *cap* gene are derived from AAV5. In some aspects, one or more of the multiple genes of a dual

helper plasmid are derived from AAV6. For instance, in some aspects, the *rep* gene is derived from AAV6. In some aspects, the *cap* gene is derived from AAV6. In some aspects, both the *rep* gene and the *cap* gene are derived from AAV6. In some aspects, one or more of the multiple genes of a dual helper plasmid are derived from AAV7. For instance, in some aspects, the *rep* gene is derived from AAV7. In some aspects, the *cap* gene is derived from AAV7. In some aspects, both the *rep* gene and the *cap* gene are derived from AAV7. In some aspects, one or more of the multiple genes of a dual helper plasmid are derived from AAV8. For instance, in some aspects, the *rep* gene is derived from AAV8. In some aspects, the *cap* gene is derived from AAV8. In some aspects, both the *rep* gene and the *cap* gene are derived from AAV8. In some aspects, one or more of the multiple genes of a dual helper plasmid are derived from AAV9. For instance, in some aspects, the *rep* gene is derived from AAV9. In some aspects, the *cap* gene is derived from AAV9. In some aspects, both the *rep* gene and the *cap* gene are derived from AAV9. In some aspects, one or more of the multiple genes of a dual helper plasmid are derived from AAVrh10. For instance, in some aspects, the *rep* gene is derived from AAVrh10. In some aspects, the *cap* gene is derived from AAVrh10. In some aspects, both the *rep* gene and the *cap* gene are derived from AAVrh10.

[134] To further illustrate, in some aspects, a dual helper plasmid of the present disclosure comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *rep* gene is derived from AAV2. The nucleic acid sequence for the AAV2 *rep* gene is set forth in SEQ ID NO: 29. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *rep* gene comprises a nucleic acid sequence that has at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the sequence set forth in SEQ ID NO: 29. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *rep* gene comprises the nucleic acid sequence set forth in SEQ ID NO: 29.

[135] In some aspects, a dual helper plasmid described herein comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *cap* gene is derived from AAV2, AAV5, AAV8, or AAV9.

[136] In some aspects, the *cap* gene is derived from AAV2. Accordingly, in some aspects, a dual helper plasmid described herein comprises a *rep* gene derived from AAV2 (*rep2*) and a *cap* gene derived from AAV2 (*cap2*). The nucleic acid sequence for the AAV2 *cap* gene is set forth in SEQ ID NO: 30. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *cap* gene comprises a nucleic acid sequence that has at least about 80%, at least about 85%,

at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity the sequence set forth in SEQ ID NO: 30. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *cap* gene comprises the nucleic acid sequence set forth in SEQ ID NO: 30.

[137] In some aspects, the *cap* gene is derived from AAV5. For instance, in some aspects, a dual helper plasmid described herein comprises a *rep* gene derived from AAV2 (*rep2*) and a *cap* gene derived from AAV5 (*cap5*). The nucleic acid sequence for the AAV5 *cap* gene is set forth in SEQ ID NO: 31. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *cap* gene comprises a nucleic acid sequence that has at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity the sequence set forth in SEQ ID NO: 31. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *cap* gene comprises the nucleic acid sequence set forth in SEQ ID NO: 31.

[138] In some aspects, the *cap* gene is derived from AAV8. For instance, in some aspects a dual helper plasmid described herein comprises a *rep* gene derived from AAV2 (*rep2*) and a *cap* gene derived from AAV8 (*cap8*). The nucleic acid sequence for the AAV8 *cap* gene is set forth in SEQ ID NO: 32. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *cap* gene comprises a nucleic acid sequence that has at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity the sequence set forth in SEQ ID NO: 32. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *cap* gene comprises the nucleic acid sequence set forth in SEQ ID NO: 32.

[139] In some aspects, the *cap* gene is derived from AAV9. For instance, in some aspects a dual helper plasmid described herein comprises a *rep* gene derived from AAV2 (*rep2*) and a *cap* gene derived from AAV9 (*cap9*). The nucleic acid sequence for the AAV9 *cap* gene is set forth in SEQ ID NO: 33. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *cap* gene comprises a nucleic acid sequence that has at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about

98%, at least about 99%, or about 100% sequence identity the sequence set forth in SEQ ID NO: 33. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *cap* gene comprises the nucleic acid sequence set forth in SEQ ID NO: 33.

[140] In some aspects, a dual helper plasmid provided herein comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *E2a* gene is derived from adenovirus serotype 5 (Ad5). The nucleic acid sequence for the Ad5 *E2a* gene is set forth in SEQ ID NO: 34. Accordingly, in some aspects, a dual helper plasmid useful for the present disclosure comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *E2a* gene comprises a nucleic acid sequence that has at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity the sequence set forth in SEQ ID NO: 34. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *E2a* gene comprises the nucleic acid sequence set forth in SEQ ID NO: 34.

[141] In some aspects, a dual helper plasmid provided herein comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *E4* gene is derived from adenovirus serotype 5 (Ad5). The nucleic acid sequence for the Ad5 *E4* gene is set forth in SEQ ID NO: 35. Accordingly, in some aspects, a dual helper plasmid useful for the present disclosure comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *E4* gene comprises a nucleic acid sequence that has at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity the sequence set forth in SEQ ID NO: 35. In some aspects, a dual helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *E4* gene comprises the nucleic acid sequence set forth in SEQ ID NO: 35.

[142] In some aspects, a dual helper plasmid provided herein comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *VA RNA* gene is derived from adenovirus serotype 5 (Ad5). The nucleic acid sequence for the Ad5 *VA RNA* gene is set forth in SEQ ID NO: 36. Accordingly, in some aspects, a dual helper plasmid useful for the present disclosure comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *VA RNA* gene comprises a nucleic acid sequence that has at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity the sequence set forth in SEQ ID NO: 36. In some aspects, a dual

helper plasmid comprises *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene, wherein the *VA RNA* gene comprises the nucleic acid sequence set forth in SEQ ID NO: 36.

[143] As is apparent from the present disclosure, in some aspects, the dual helper plasmids described herein comprise genes derived from the same viral source or from multiple viral sources. In some aspects, a dual helper plasmid described comprises: (i) an *E2a* gene derived from Ad5 (e.g., SEQ ID NO: 34); (ii) an *E4* gene derived from Ad5 (e.g., SEQ ID NO: 35); (iii) a *VA RNA* gene derived from Ad5 (e.g., SEQ ID NO: 36), (iv) a *cap* gene derived from AAV2 (e.g., SEQ ID NO: 30); and (v) a *rep* gene derived from AAV2 (e.g., SEQ ID NO: 29). In some aspects, a dual helper plasmid described comprises: (i) an *E2a* gene derived from Ad5 (e.g., SEQ ID NO: 34); (ii) an *E4* gene derived from Ad5 (e.g., SEQ ID NO: 35); (iii) a *VA RNA* gene derived from Ad5 (e.g., SEQ ID NO: 36), (iv) a *cap* gene derived from AAV5 (e.g., SEQ ID NO: 31); and (v) a *rep* gene derived from AAV2 (SEQ ID NO: 29). In some aspects, a dual helper plasmid described comprises: (i) an *E2a* gene derived from Ad5 (e.g., SEQ ID NO: 34); (ii) an *E4* gene derived from Ad5 (e.g., SEQ ID NO: 35); (iii) a *VA RNA* gene derived from Ad5 (e.g., SEQ ID NO: 36), (iv) a *cap* gene derived from AAV8 (e.g., SEQ ID NO: 32); and (v) a *rep* gene derived from AAV2 (e.g., SEQ ID NO: 29). In some aspects, a dual helper plasmid described comprises: (i) an *E2a* gene derived from Ad5 (e.g., SEQ ID NO: 34); (ii) an *E4* gene derived from Ad5 (e.g., SEQ ID NO: 35); (iii) a *VA RNA* gene derived from Ad5 (e.g., SEQ ID NO: 36), (iv) a *cap* gene derived from AAV9 (e.g., SEQ ID NO: 33); and (v) a *rep* gene derived from AAV2 (e.g., SEQ ID NO: 29).

[144] As described and demonstrated herein, the arrangement of one or more of the genes described above (e.g., *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene) can help improve certain properties of the dual helper plasmids of the present disclosure. For instance, in some aspects, a dual helper plasmid described comprises: (i) an *E2a* gene derived from Ad5 (e.g., SEQ ID NO: 34); (ii) an *E4* gene derived from Ad5 (e.g., SEQ ID NO: 35); (iii) a *VA RNA* gene derived from Ad5 (e.g., SEQ ID NO: 36), (iv) a *cap* gene derived from AAV2, AAV5, AAV8, or AAV9 (e.g., SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, or SEQ ID NO: 33, respectively); and (v) a *rep* gene derived from AAV2 (e.g., SEQ ID NO: 29), wherein the *rep* gene and the *cap* gene are in a clockwise direction. For instance, in some aspects, the 5'-terminal of the *rep* gene is linked to the 5'-terminal of the *E2a* gene, wherein the 3'-terminal of the *rep* gene is linked to the 5'-terminal of the *cap* gene, and wherein the 3'-terminal of the *cap* gene is linked to 3'-terminal of the *VA RNA* gene. See, e.g., FIG. 5A. In some aspects, a dual helper plasmid described comprises: (i) an *E2a* gene derived from Ad5 (e.g., SEQ ID NO: 34); (ii) an *E4* gene derived from Ad5 (e.g., SEQ ID NO: 35); (iii) a *VA RNA* gene

derived from Ad5 (*e.g.*, SEQ ID NO: 36), (iv) a *cap* gene derived from AAV2, AAV5, AAV8, or AAV9 (*e.g.*, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, or SEQ ID NO: 33, respectively); and (v) a *rep* gene derived from AAV2 (*e.g.*, SEQ ID NO: 29), wherein the *rep* gene and the *cap* gene are in a counterclockwise direction. In some aspects, the 5'-terminal of the *rep* gene is linked to the 3'-terminal of the *VA RNA* gene, wherein the 3'-terminal of the *rep* gene is linked to the 5'-terminal of the *cap* gene, and wherein the 3'-terminal of the *cap* gene is linked to the 5'-terminal of the *E2a* gene. *See, e.g.*, FIG. 5B.

[145] Based on at least the features described herein (*e.g.*, the particular arrangements of the *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene), the dual helper plasmid of the present disclosure exhibit one or more of the following improved properties: 1) increased chance of cotransfection such that host cell has all the necessary components to produce a recombinant AAV, 2) increased productivity of recombinant adeno-associated virus, and 3) reduction in cost and time of plasmid production and purification. Additional disclosure relating to such properties are provided elsewhere in the present disclosure.

[146] **II.B. Additional Features**

[147] As is apparent from the present disclosure, in some aspects, the dual helper plasmids described herein comprise one or more additional features that are useful in a recombinant AAV production. For instance, in some aspects, the dual helper plasmid described herein further includes an antibiotic resistance gene. For instance, in some aspects, the dual helper plasmids further comprises a selection marker. As used herein, the term "**selection marker**" refers to any gene that can be used to identify cells that express a nucleic acid sequence. Accordingly, such selection marker can be used to identify and enrich for the transformed cells after transfection with the dual helper plasmids described herein. The selection markers that can be used with the present disclosure include any suitable selection markers known in the art. Non-limiting examples of suitable selection markers include (i) enzymes encoding resistance to an antibiotic (*i.e.*, "antibiotic resistance gene"), *e.g.*, kanamycin, neomycin, puromycin, hygromycin, blasticidin, or zeocin; or (ii) fluorescent proteins, for example green fluorescent protein (GFP), red fluorescent protein (RFP) or blue fluorescent protein (BFP).

[148] In some aspects, the selection marker comprises an antibiotic resistance gene. In some aspects, the antibiotic resistance gene comprises an ampicillin resistance gene, kanamycin resistance gene, or both. The nucleic acid sequence for the ampicillin resistance gene is set forth in SEQ ID NO 37. The nucleic acid sequence for the kanamycin resistance gene is set forth in SEQ ID NO 38.

[149] **III. Expression Construct**

[150] As is apparent from the present disclosure, in some aspects, the dual helper plasmids provided herein can be used in combination with one or more additional plasmids, *e.g.*, in producing a recombinant AAV. In some aspects, the additional plasmid comprises a recombinant expression construct, *e.g.*, an AAV construct plasmid (referred to herein as "**expression construct**"). Exemplary aspects of such expression constructs are described below.

[151] III.A. Transgene (*e.g.*, flanked by ITRs)

[152] As further described elsewhere in the present disclosure, in some aspects, a dual helper plasmid provided herein comprises a *E2a* gene, *E4* gene, *VA RNA* gene, *rep* gene, and *cap* gene. In such aspects, the transgene (*e.g.*, which is to be introduced into the recombinant AAV that is produced) can be provided by a separate expression construct (*e.g.*, AAV construct plasmid). Accordingly, in some aspects, the expression construct comprises a transgene. In some aspects, the transgene is flanked by inverted terminal repeats (ITRs). Transgenes useful for the present disclosure is not particularly limited as long as the transgene can be translated into a polypeptide when introduced into a cell. Accordingly, any suitable transgenes of interest can be used with present disclosure. In some aspects, a transgene encodes a polypeptide (or any variant thereof), fusion protein, antibody or an antigen-binding fragment thereof, a RNA-based molecule (*e.g.*, miRNA, shRNA, ribozyme, siRNA), or any combination thereof.

[153] In some aspects, a transgene encodes a protein that is useful for the treatment of a disease or disorder, such as those described herein. In some aspects, the transgene encodes a therapeutic peptide for a specific disease for the purpose of sustained expression in the body of a subject or patient.

[154] III.B. Control Elements

[155] In some aspects, the expression construct that can be used with the dual helper plasmids of the present disclosure further comprises a control element. In some aspects, the control element is operably linked to the transgene.

[156] Accordingly, in some aspects, an expression construct described herein (*e.g.*, AAV construct plasmid) comprises:

[157] (a) an ITR (inverted terminal repeat);

[158] (b) a transgene; and

[159] (c) a control element operably linked to the transgene.

[160] Control elements useful for the present disclosure comprises an enhancer (*e.g.*, CMV enhancer), a promoter (*e.g.*, CMV promoter, EF-1 α promoter, β -actin promoter), an exon (*e.g.*, exon 1, exon 2), an intron (*e.g.*, intron A), a splicing donor or acceptor sequence, or combinations thereof. In some aspects, the control element can include a sequence for transcription termination (*e.g.*, poly A), a sequence for stable transgene expression (*e.g.*, WPRE sequence), a sequence for reducing transgene-specific

immunity (e.g., miRNA target sequence), or combinations thereof. Details about the transgene and the control element (ITR sequence, enhancer sequence, promoter sequence, E1 sequence, splicing donor sequence, EF-1 α intron or its fragment sequence including splicing acceptor, EF-1 α E2 sequence, WPRE sequence, miR sequence, poly A sequence, etc.) can be found in US 2022/0010332 A1, which is incorporated herein by reference in its entirety.

[161] As described above, in some aspects, an expression construct useful for the present disclosure comprises (i) a transgene and (ii) a control element operably linked to the transgene, wherein the control element includes the following components:

[162] 1) a CMV enhancer sequence;

[163] 2) a CMV promoter sequence, EF-1 α promoter sequence, or chicken β -actin promoter sequence;

[164] 3) a CMV E1 sequence, EF-1 α E1 sequence, or chicken β -actin E1 sequence;

[165] 4) a splicing donor sequence;

[166] 5) an EF-1 α intron fragment sequence; and

[167] 6) an EF-1 α E2 sequence.

[168] **IV. Vectors**

[169] In some aspects, provided herein are vectors, *e.g.*, comprising any of the plasmids provided herein (*e.g.*, dual helper plasmid and/or expression construct comprising a transgene). Also provided herein are recombinant AAVs produced using the plasmids provided herein. As described herein, such vectors are useful for recombinant expression in host cells and cells targeted for therapeutic intervention.

[170] As is apparent from the present disclosure, in some aspects, vectors useful for the present disclosure are derived from AAV. AAV possesses unique features that make it attractive as a vector system for delivering foreign DNA into cells. AAV infection of cells in culture has generally been noncytopathic, and natural infection of humans and other animals is silent and asymptomatic. Moreover, AAV infects many different types of mammalian cells allowing the possibility of targeting many different tissues *in vivo*. AAV also possesses additional advantages that make it a particularly attractive viral system for gene delivery, including the promotion of an immune response that is relatively mild compared to other forms of gene delivery, and persistent expression in both dividing and quiescent cells based on non-integrating, episomal vector DNA. Also, AAV withstands the conditions used to inactivate adenovirus (56° to 65° C for several hours), making cold preservation of rAAV-based vaccines less critical.

[171] Non-limiting examples of the types or serotypes of adeno-associated viruses that can be used with the present disclosure are provided elsewhere in the present disclosure.

[172] **V. Cells**

[173] In some aspects, the present disclosure provides cells comprising the plasmids

described herein (*e.g.*, dual helper plasmid and expression construct comprising a transgene) (also referred to herein as "**modified cells**"). In some aspects, the cells (*e.g.*, a host cell) have been transfected with a dual helper plasmid and an AAV construct plasmid to produce a recombinant AAV. . As described herein, in some aspects, the modified cells of the present disclosure (*e.g.*, comprising a dual helper plasmid and an expression construct comprising a transgene) are capable of improving one or more aspects of recombinant AAV production. For instance, in some aspects, the modified cells provided herein allow for greater yield when producing a recombinant AAV, as compared to a reference cell. In some aspects, the reference cell comprises a corresponding cell that was modified to comprise the following three separate plasmids: (1) first plasmid comprising a *rep* gene and a *cap* gene ("**rep-cap plasmid**"); (2) second plasmid comprising an *E2a* gene, *E4* gene, and *VA RNA* gene ("**helper plasmid**"); and (3) third plasmid comprising a transgene.

[174] In some aspects, compared to the reference cell, cells of the present disclosure (*e.g.*, comprising a dual helper plasmid and an expression vector comprising a transgene) are capable of increasing the amount of recombinant AAV produced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more. In some aspects, compared to the reference cells, cells of the present disclosure are capable of increasing the amount of recombinant AAV produced by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, at least about 50-fold, at least about 75-fold, or at least about 100-fold or more. In some aspects, cells provided herein (*e.g.*, modified to comprise a dual helper plasmid and an expression construct comprising a transgene) allow for reduced production and/or purification time compared to the reference cells. In some aspects, compared to the reference cell, the production and/or purification time is decreased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% or more.

[175] As is apparent from the present disclosure, also provided herein are cells provided herein have been modified (*e.g.*, transfected) to comprise the recombinant AAV produced using the plasmids described herein. Such cells can be particularly useful for producing a protein, *e.g.*, encoded by a transgene described herein. Not to be bound by any one theory, in some aspects, when a cell (*e.g.*, host cell) is transfected with the plasmids described herein (*e.g.*, dual helper plasmid and expression construct

comprising a transgene operably linked to a control element), the resulting recombinant AAV produced comprises one or more features of the individual plasmids. For instance, in some aspects, the resulting recombinant AAV comprises the transgene operably linked to the control element.

[176] As described herein, in some aspects, the one or more control elements described herein can enhance the expression of the protein encoded by the transgene ("encoded protein") in a cell. Accordingly, in some aspects, a cell described herein (*e.g.*, transfected with a recombinant AAV delivery vector comprising a transgene operably linked to one or more control elements described herein) produces greater expression of the encoded protein compared to a reference cell. In some aspects, the reference cell is transfected with a corresponding delivery vector but lacking one or more of the control elements described herein.

[177] In some aspects, the cells described herein are modified (*e.g.*, transfected) *in vitro* to produce a composition of interest. For instance, in some aspects, the cells are transfected *in vitro* with a dual helper plasmid and an expression construct (*e.g.*, such as those described herein) to produce a recombinant AAV. In some aspects, the cells are transfected *in vitro* with the recombinant gene delivery vector to produce the protein encoded by the transgene. In some aspects, the cells described herein can produce the encoded protein *in vivo* (*e.g.*, in a subject that received an administration of the recombinant AAV comprising the transgene). In some aspects, the cells described herein can produce the composition of interest (*e.g.*, encoded protein) both *in vitro* and *in vivo*.

[178] As described herein, in some aspects, the present disclosure provides a host cell transformed, transduced or transfected with, *e.g.*, the recombinant expression construct for transgene expression. As used herein, the term "**host cell**" includes eukaryotic cells and prokaryotic cells, and refers to a cell of an organism that can be transduced, *e.g.*, so that a gene encoded by a plasmid or an expression construct (*e.g.*, AAV construct plasmid, Rep-Cap plasmid, helper plasmid, dual helper plasmid, etc.) can be expressed or replicated. In some aspects, it refers to an isolated (eukaryotic) host cell. As used herein, the term "**transfection**" is intended to include transduction and transformation. The host cell can be transfected, transduced, or transformed with any of the plasmids, constructs, and/or vectors described herein. The term means a process whereby an exogenous nucleic acid molecule is delivered or introduced into the host cell.

[179] In some aspects, the host cell is a eukaryotic cell. In some aspects, the host cell is selected from the group consisting of a mammalian cell, an insect cell, a yeast cell, a transgenic mammalian cell, and a plant cell. In some aspects, the host cell is a prokaryotic cell. In some aspects, the prokaryotic cell is a bacterial cell.

[180] In some aspects, cells useful for the present disclosure (*e.g.*, host cells) comprise an

insect cell, a mammalian cell, or both. In some aspects, the insect cell can be Sf9 cell. In some aspects, the mammalian cell comprises HEK293 cell, HeLa cell, ARPE-19 cell, RPE-1 cell, HepG2 cell, Hep3B cell, Huh-7 cell, C8D1a cell, Neuro2A cell, CHO cell, MES13 cell, BHK-21 cell, COS7 cell, COP5 cell, A549 cell, MCF-7 cell, HC70 cell, HCC1428 cell, BT-549 cell, PC3 cell, LNCaP cell, Capan-1 cell, Panc-1 cell, MIA PaCa-2 cell, SW480 cell, HCT166 cell, LoVo cell, A172 cell, MKN-45 cell, MKN-74 cell, Kato-III cell, NCI-N87 cell, HT-144 cell, SK-MEL-2 cell, SH-SY5Y cell, C6 cell, HT-22 cell, PC-12 cell, NIH3T3 cell, or combinations thereof.

[181] In some aspects, a cell useful for the present disclosure comprises a human cell. In some aspects, the human cell is a cell of a subject that is to receive an administration of a recombinant gene delivery vector described herein. In some aspects, the human cell is from a donor (*e.g.*, healthy human subject).

[182] **VI. Composition**

[183] The present disclosure is also directed to compositions comprising the dual helper plasmids described herein. As is apparent from the present disclosure, in some aspects, such compositions further comprise an additional plasmid, such as the expression constructs described herein (*e.g.*, an AAV construct plasmid for transgene expression). As further described elsewhere in the present disclosure, such compositions can be useful in producing a recombinant AAV.

[184] The various plasmids (*e.g.*, dual helper plasmid), constructs (*e.g.*, expression construct), vectors (*e.g.*, recombinant AAV delivery vector), and cells disclosed herein (also referred to herein as "**active compounds**") can be incorporated into pharmaceutical compositions suitable for administration. Accordingly, in some aspects, the present disclosure is directed to such pharmaceutical compositions. For instance, in some aspects, the present disclosure provides a pharmaceutical composition comprising a recombinant AAV produced using the plasmids described herein (*e.g.*, dual helper plasmids).

[185] In some aspects, the pharmaceutical compositions described herein further comprises a pharmaceutically acceptable carrier.

[186] The pharmaceutically acceptable carriers that can be used with the present disclosure include those that are commonly used for formulation. Non-limiting examples of such pharmaceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, and combinations thereof. The pharmaceutical compositions of the present disclosure can further comprise one or more additives, such as a lubricant, a wetting agent, sweetener, a flavorant, an emulsifier, a suspending agent, a preservative, and

combinations thereof. Additional details of suitable pharmaceutically acceptable carriers and formulations are described in Remington's Pharmaceutical Sciences (19th ed., 1995).

[187] A pharmaceutical composition of the disclosure is formulated to be compatible with an intended route of administration. Non-limiting examples of such administration routes are provided elsewhere in the present disclosure.

[188] The pharmaceutical compositions described herein can be provided as a single-dosage or in multiple-dosage forms. In some aspects, a pharmaceutical composition provided herein is formulated in the form of a solution (*e.g.*, in an oily or aqueous medium), a suspension, an emulsion, an extract, a powder, a granule, a tablet or a capsule. In some aspects, a formulation comprising a pharmaceutical composition described herein can further contain a dispersant, a stabilizer, or both.

[189] **VII. Kits**

[190] Also disclosed herein are kits comprising one or more of the various plasmids (*e.g.*, dual helper plasmid), constructs (*e.g.*, expression construct), vectors (*e.g.*, recombinant AAV delivery vector), cells, and compositions (*e.g.*, pharmaceutical compositions) disclosed herein. In some aspects, the kit also comprises instructions for use (*e.g.*, for administering any of the aforesaid, or a combination thereof, to a subject in need thereof).

[191] The terms "**kit**" and "**system**," as used herein, are intended to refer to at least one or more of the various plasmids (*e.g.*, dual helper plasmid), constructs (*e.g.*, expression construct), vectors (*e.g.*, recombinant AAV delivery vector), cells, and compositions (*e.g.*, pharmaceutical compositions), or any combination thereof, which, in some aspects, are in combination with one or more other types of elements or components (*e.g.*, other types of biochemical reagents, containers, packages, such as packaging intended for commercial sale, instructions of use, and the like).

[192] **VIII. Uses and Methods**

[193] VIII.A. Methods of Producing AAVs

[194] Certain aspects of the present disclosure relate to methods of producing an AAV. More specifically, in some aspects, provided herein are methods of producing a recombinant AAV comprising a transgene. In some aspects, such methods comprise transfecting a cell (*e.g.*, host cell) with a dual helper plasmid (such as those described herein) and an expression construct (*e.g.*, AAV construct plasmid) comprising a transgene. In some aspects, the cell is transfected with the dual helper plasmid and the expression construct concurrently. In some aspects, the cell is transfected with the dual helper plasmid and the expression construct sequentially. Unless indicated otherwise, any suitable transfection methods known in the art can be used with the present disclosure.

- [195] In some aspects, the method of producing a recombinant AAV further comprises culturing the transfected cells under suitable conditions such that the recombinant AAVs are produced. In some aspects, the method further comprises recovering the produced recombinant AAV.
- [196] The methods of producing recombinant AAVs described herein provide certain distinct benefits. As further described elsewhere in the present disclosure, the more traditional methods of producing an AAV require triple transfection, in which a host cell is transfected with the following three separate plasmids: i) a Rep-Cap plasmid including a gene encoding Rep protein and Cap protein; ii) a helper plasmid including a gene encoding the proteins (E2a, E4) and VA RNAs of adenovirus; and iii) an AAV construct plasmid for transgene expression. The recombinant AAV is only produced where the cells are successfully transfected with all of the above-mentioned three plasmids (*i.e.*, each of the genes are taken up and delivered to the nucleus of the cells, and subsequently transcribed, replicated, and/or translated within the cells). Because of the complexity involved, such methods requiring triple transfection can result in low yield and/or be more labor intensive and costly.
- [197] Compared to such approaches, the methods of producing a recombinant AAV provided herein can result in greater yield of the recombinant AAVs. In some aspects, compared to methods requiring triple transfection (*i.e.*, "**reference method**"), the amount of recombinant AAV produced is increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more. In some aspects, compared to the reference cells, cells of the present disclosure are capable of increasing the amount of recombinant AAV produced by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, at least about 50-fold, at least about 75-fold, or at least about 100-fold or more.
- [198] As further described elsewhere in the present disclosure, in some aspects, the methods of producing a recombinant AAV provided herein can result in reduced production and/or purification time. Additional benefits are described elsewhere in the present disclosure.
- [199] VIII.B. Methods of Producing Protein
- [200] Also disclosed herein are methods of producing a protein (or polypeptide) encoded by a transgene. In some aspects, such a method comprises culturing a cell described herein (*e.g.*, transfected with a recombinant AAV delivery vector comprising a transgene) under suitable conditions and recovering the encoded protein. In certain

aspects, a method of producing a protein encoded by a transgene comprises administering a recombinant AAV to a subject in need thereof, such that the encoded polypeptide is produced in the subject. Additional disclosure relating to such *in vivo* method of producing a protein is provided elsewhere in the present disclosure.

[201] VIII.C. Therapeutic Uses

[202] In some aspects, the present disclosure further provides a use of a recombinant AAV produced using the dual helper plasmids of the present disclosure for various therapeutic applications.

[203] For instance, in some aspects, the present disclosure provides a method for treating a disease in a subject in need thereof, comprising administering to the subject a recombinant AAV comprising a transgene and produced as described herein. In some aspects, a method of treating a disease provided herein comprises administering to a subject in need thereof any of the modified cells described herein (*e.g.*, transfected with the recombinant AAV gene delivery vector comprising a transgene). In some aspects, a method of treating a disease provided herein comprises administering to a subject in need thereof any of the pharmaceutical compositions described herein (*e.g.*, comprising the recombinant AAV provided herein). As is apparent from the present disclosure, the above methods can be used to treat and/or prevent any disease of interest, *e.g.*, by modifying the transgene.

[204] The disease to be prevented, alleviated, or treated by the present disclosure is not limited but includes all diseases that require reduced number of a drug administration. Non-limiting examples of such diseases include ophthalmic diseases and neurological diseases. In some aspects, ophthalmic diseases comprise diabetic retinopathy, choroidal neovascularization, macular degeneration, retinal degeneration, macular edema, retinal edema, macular tumentia, or a combination thereof. In some aspects, neurological diseases comprise those that affect the central nervous system, the peripheral nervous system, or both. Non-limiting examples of neurological diseases include: anxiety, depression, post-traumatic stress disorder (PTSD), bipolar disorder, attention deficit hyperactivity disorder (ADHD), autism, schizophrenia, neuropathic pain, glaucoma, toxicosis, arachnoid cyst, catatonia, encephalitis, epilepsy/seizure, locked-in syndrome, meningitis, migraine, multiple sclerosis, myelopathy, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Batten disease, Tourette's syndrome, traumatic brain injury, cerebrospinal injury, stroke, tremor (essential or Parkinsonian), dystonia, intellectual disability, brain tumor or a combination thereof.

[205] Some aspects of the present disclosure relate to gene therapy agent that can achieve continuous expression of a transgene or a method using such agents for treating a disease.

- [206] Use of a gene delivery system provided herein (*e.g.*, recombinant AAVs comprising a transgene) allows administration of the therapeutic agent (*e.g.*, recombinant AAVs comprising the transgene) at intervals that can significantly reduce the number of drug administration for the convenience of physicians, patients or subjects. For instance, in some aspects, the therapeutic agent can be administered at intervals of about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, or about 1 year or more. In some aspects, the interval is about 2 to about 3 months. In some aspects, the interval is about 6 months. In some aspects, the interval is about 1 year. In some aspects, the interval is at least about 1 year. In some aspects, depending on the symptoms of a patient, the administration can be made about 2 or 3 times with an interval of about 1-2 weeks in the early stage, followed by administration with an interval of about 2-3 months, about 6 months, or about 1 year or longer, if necessary.
- [207] In any of the methods provided herein comprising an administration step (*e.g.*, administering any of the AAVs, cells, and/or pharmaceutical compositions described herein to a subject in need thereof), the therapeutic agent can be administered to the subject orally or parenterally. In some aspects, the therapeutic agent (*e.g.*, any of the AAVs, cells, and/or pharmaceutical compositions described herein) is administered to the subject parenterally. Non-limited examples of parenteral administration include: intravenous injection, transdermal administration, subcutaneous injection, intramuscular injection, intravitreal injection, subretinal injection, suprachoroidal injection, eye drop administration, intracerebroventricular injection, intrathecal injection, intraamniotic injection, intraarterial injection, intraarticular injection, intracardiac injection, intracavernous injection, intracerebral injection, intracisternal injection, intracoronary injection, intracranial injection, intradural injection, epidural injection, intrahippocampal injection, intranasal injection, intraosseous injection, intraperitoneal injection, intrapleural injection, intraspinal injection, intrathoracic injection, intrathymic injection, intrauterine injection, intravaginal injection, intraventricular injection, intravesical injection, subconjunctival injection, intratumoral injection, topical injection, intraperitoneal injection, and combinations thereof.
- [208] As will be apparent to those skilled in the arts, appropriate administration dosage of a therapeutic agent (*e.g.*, the pharmaceutical composition of the present disclosure) can vary depending on factors, such as, formulation method, mode of administration, the age, body weight, sex, pathological condition and diet of a patient, administration time, administration route, excretion rate and response sensitivity. In some aspects, a daily administration dosage of a therapeutic agent (*e.g.*, the pharmaceutical composition of the present disclosure) is about 0.00001-100 mg/kg.

[209]

[210] Hereinafter, the present disclosure is described in further detail through examples. The following examples are only for illustrating the present disclosure more specifically, and it will be obvious to those having ordinary knowledge in the art that the scope of the present disclosure is not limited by the examples.

[211]

[212] **Examples**

[213] ***Materials and methods***

[214] **Example 1. Preparation of pUC-R2C2, 5, 8 and 9 constructs for triple transfection**

[215] **Example 1-1. Preparation of pRC8 construct**

[216] A *cap8* gene fragment was obtained by conducting polymerase chain reaction (hereinafter, PCR) using pIDT-Cap8-Kan (Integrated DNA Technologies, USA) as a template and using a combination of oligo #001/002, and a plasmid backbone DNA fragment including the *rep2* gene was obtained by conducting PCR using pRC6 (Takara Bio, Japan) as a template and using a combination of oligo #003/004. A pRC8 construct was prepared by joining the two DNA fragments through Gibson Assembly® (NEB, USA, Cat. No. E2611).

[217]

[218] **Example 1-2. Preparation of pUC-R2C8 construct**

[219] A plasmid backbone was obtained by conducting PCR using pUC57-WPRE (GenScript, USA) as a template and using a combination of oligo #005/006, and a *cap8* gene fragment and a *rep2* gene fragment were obtained by conducting PCR using the pRC8 construct of Example 1-1 as a template and using oligo #007/008 and oligo #009/004, respectively. A pUC-R2C8 construct was prepared by joining the three DNA fragments through Gibson Assembly®.

[220]

[221] **Example 1-3. Preparation of pRC2 construct**

[222] A *cap2* gene fragment was obtained by conducting PCR using pRC2-mi342 (Takara Bio, Japan) as a template and using a combination of oligo #007/010, and a plasmid backbone fragment including the *rep2* gene was obtained by conducting PCR using pRC6 (Takara Bio, Japan) as a template and using a combination of oligo #003/004. A pRC2 construct was prepared by joining the two DNA fragments through Gibson Assembly®.

[223]

[224] **Example 1-4. Preparation of pUC-R2C2 construct**

[225] A plasmid backbone fragment including the *rep2* gene was obtained by conducting PCR using the pUC-R2C8 construct of Example 1-2 as a template and using a com-

ination of oligo #011/012, and a *cap2* gene fragment was obtained by conducting PCR using the pRC2 construct of Example 1-3 as a template and using a combination of oligo #013/014. A pUC-R2C2 construct was prepared by joining the two DNA fragments through Gibson Assembly®.

[226]

[227] **Example 1-5. Preparation of pRC9 construct**

[228] A *cap9* gene fragment was obtained by conducting PCR using pIDT-Cap9-Kan (Integrated DNA Technologies, USA) as a template and using a combination of oligo #001/015, and a plasmid backbone fragment including the *rep2* gene was obtained by conducting PCR using pRC6 (Takara Bio, Japan) as a template and using a combination of oligo #003/004. A pRC9 construct was prepared by joining the two DNA fragments through Gibson Assembly® (NEB, USA, Cat. No. E2611).

[229]

[230] **Example 1-6. Preparation of pUC-R2C9 construct**

[231] A plasmid backbone was obtained by conducting PCR using pUC57-WPRE (GenScript, USA) as a template and using a combination of oligo #005/006 combination, and a *cap9* gene fragment and a *rep2* gene fragment were obtained by conducting PCR using the pRC9 construct of Example 1-5 as a template and using oligo #007/008, and using the pRC8 construct of Example 1-1 as a template and using oligo #009/004, respectively. A pUC-R2C9 construct was prepared by joining the three DNA fragments through Gibson Assembly®.

[232]

[233] **Example 1-7. Preparation of pUC-R2C5 construct**

[234] A plasmid backbone was obtained by conducting PCR using pUC57-WPRE (GenScript, USA) as a template and using a combination of oligo #005/006, and a *rep2-cap5* gene fragment was obtained by conducting PCR using a pRC5 construct (Takara Bio, Japan) as a template and using oligo #008/009. A pUC-R2C5 construct was prepared by joining the two DNA fragments through Gibson Assembly®.

[235]

[236] **Example 2. Preparation of pHION8 series constructs**

[237] **Example 2-1. Preparation of pHelper-NG construct**

[238] A pHelper-NG was prepared through cloning by joining VA-E4-pUC (GeneScript, USA) and E2a-pUC57 (GeneScript, USA) using the Sall/BamHI site shared by the two constructs (FIG. 1A). The pHelper-NG includes the *E2a*, *E4* and *VA RNA* genes of adenovirus serotype 5.

[239]

[240] **Example 2-2. Insertion of *rep2-cap8* gene at different locations of pHelper-NG construct**

[241] **Example 2-2-1. Cloning of pHION8-BamHI-Forward or Reverse (pHION8-BF or -BR)**

[242] A *rep2-cap8* gene fragment was obtained by conducting PCR using the pUC-R2C8 construct of Example 1-2 as a template and using a combination of oligo #016/017 and inserted at the BamHI site of the pHelper-NG prepared in Example 2-1 (FIGS. 1B and 1C). FIG. 1B schematically shows a pHION8-BF construct, which was prepared by inserting the *rep2-cap8* gene fragment in a forward direction (clockwise direction, 5' -> 3') using the BamHI site present between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene. FIG. 1C schematically shows a pHION8-BR construct, which was prepared by inserting the *rep2-cap8* construct in a reverse direction (counterclockwise direction, 3' -> 5') using the BamHI site present between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene. The pHION8-BF was named as pHNG8, and pHION8-BR as pHNGR8.

[243]

[244] **Example 2-2-2. Cloning of pHION8-NotI-Forward or -Reverse (pHION8-NF or -NR)**

[245] A *rep2-cap8* gene fragment was obtained by conducting PCR using the pUC-R2C8 construct of Example 1-2 as a template and using a combination of oligo #018/019 and inserted at the NotI site of the pHelper-NG prepared in Example 2-1 (FIGS. 1D and 1E). FIG. 1D schematically shows a pHION8-NF construct, which was prepared by inserting the *rep2-cap8* gene fragment in a forward direction (clockwise direction) using the NotI site present between the beginning portion of the *E4* gene and the beginning portion of the AmpR gene. FIG. 1E schematically shows a pHION8-NR construct, which was prepared by inserting the *rep2-cap8* gene fragment in a reverse direction (counterclockwise direction) using the NotI site present between the beginning portion of the *E4* gene and the beginning portion of the AmpR gene.

[246]

[247] **Example 2-2-3. Cloning of pHION8-AsiSI-Forward (pHION8-AF)**

[248] A pHION8-AF construct was prepared by obtaining a *rep2-cap8* gene fragment by conducting PCR using the pUC-R2C8 construct of Example 1-2 as a template and using a combination of oligo #020/021 and inserting in a forward direction (clockwise direction) at the AsiSI site of the pHelper-NG prepared in Example 2-1 between the *VA RNA* gene and the *E4* gene (FIG. 1F).

[249]

[250] **Example 3. Preparation of pHNG2, pHNG5K and pHNG9 constructs**

[251] **Example 3-1. Preparation of pHNG2 construct**

[252] A construct prepared by obtaining a *rep2-cap2* gene fragment by conducting PCR using the pUC-R2C2 construct of Example 1-4 as a template and using oligo #016/017

and inserting the same at the BamHI site of the pHelper-NG prepared in Example 2-1 was named pHNG2.

[253] FIG. 2 schematically shows the pHNG2 construct, which was prepared by inserting the *rep2-cap2* gene fragment in a forward direction (clockwise direction) using the BamHI site present between the *E2a* gene and the *VA RNA* gene.

[254]

[255] **Example 3-2. Preparation of pHNG9 construct**

[256] A construct prepared by obtaining a *rep2-cap9* gene fragment by conducting PCR using the pUC-R2C9 construct of Example 1-6 as a template and using oligo #016/#017 and inserting the same at the BamHI site of the pHelper-NG prepared in Example 2-1 was named pHNG9. FIG. 3 schematically shows the pHNG9 construct, which was prepared by inserting the *rep2-cap9* gene fragment in a forward direction (clockwise direction) using the BamHI site present between the *E2a* gene and the *VA RNA* gene.

[257]

[258] **Example 3-3. Preparation of pHNG5K construct**

[259] **Example 3-3-1. Preparation of pHelper-NG-Kan construct**

[260] A kanamycin resistance gene fragment was obtained by conducting PCR using a pMK-RQ-1-PM construct (Geneart, Thermo Fisher Scientific, USA) as a template and using a combination of oligo #018/019, and an *E4* gene fragment, a fragment from *VA RNAs* gene to an N-term of the *E2a* gene and a fragment from a C-term of the *E2a* gene to Origin were obtained by conducting PCR using the pHelper-NG construct of Example 2-1 as a template and using oligo #020/021, oligo #022/023 and oligo #024/025, respectively. A pHelper-NG-Kan construct was prepared by joining the four DNA fragments through Gibson Assembly®.

[261]

[262] **Example 3-3-2. Insertion of *rep2-cap5* gene into pHelper-NG-Kan construct**

[263] A construct prepared by obtaining a *rep2-cap5* gene fragment by conducting PCR using the pUC-R2C5 construct of Example 1-7 as a template and using oligo #016/#017 and inserting the same at the BamHI site of the pHelper-NG-Kan prepared in Example 3-3-1 was named pHNG5K (K denotes that a kanamycin resistance gene was used as an antibiotic resistance gene). FIG. 4 schematically shows the pHNG5K construct, which was prepared by inserting the *rep2-cap5* gene fragment in a forward direction (clockwise direction) using the BamHI site present between the *E2a* gene and the *VA RNA* gene.

[264] The sequences of the oligos used to prepare the above-described constructs are shown in Table 1:

[265] [Table 1]

Oligo ID (#)	SEQ ID (#)	Sequence (5' -> 3')
001	1	TGAACAATAAATGATTTAAATCAGGTATGGCTG CCGATGGTTATCTTCCAG
002	2	TAACAAGCAATTACAGATTACGGGTGAGGTAAC GGG
003	3	TAATCTGTAATTGCTTGTTAATCAATAAACCGTT TAATTCGTTTCAG
004	4	TTTAAATCATTATTGTTCAAAGATGCAGTCATC CAAATCCAC
005	5	ATTAECTACAAGCTGTTTCCTGTGTGAAATTGTT ATCC
006	6	GCGGCTGCGCTTAAGCCAGCCCCGACACC
007	7	TGAACAATAAATGATTTAAATCAGGTATGGCTG CCG
008	8	GGAAACAGCTTGTAGTTAATGATTAACCCGCCA TGC
009	9	GCTGGCTTAAGCGCAGCCGCCATG
010	10	TAACAAGCAATTACAGATTACGAGTCAGGTATC TGG
011	11	GGTCGCTGGGGACCTTAATC
012	12	CCATGGCTACGTAGATAAGTAGCATG
013	13	GATTAAGGTCCCCAGCGACC
014	14	ACTTATCTACGTAGCCATGGAACTAGATAAGA AAGAAATACG
015	15	TAACAAGCAATTACAGATTACGAGTCAGGTATC TGGTGC
016	16	GGAAGATCTTTAAGCGCAGCCGCCATG
017	17	GGAAGATCTTGTAGTTAATGATTAACCCGCCATG C
018	18	GGCACTTTTCGGGGAAATGTG
019	19	CAATCTAAAGTATATATGAGTAAACTTGGTCTGA CAG

020	20	ATGATACCCTTGCGAATTTATCCACC
021	21	CACATTTCCCCGAAAAGTGCC
022	22	GGTGGATAAATTCGCAAGGGTATCAT
023	23	ACCTATCACATCTTTTTCCAAACTGC
024	24	GCAGTTTTGGAAAAAGATGTGATAGGT
025	25	CTGTCAGACCAAGTTTACTCATATATACTTTAGATTG
026	26	GCCAGCCATCTGTTGT
027	27	GGAGTGGCACCTTCCA
028	28	FAM-TCCCCCGTGCCTTCCTTGACC-BHQ1

[266]

[267]

And, constructs prepared by inserting the *rep-cap* gene fragment between the *E2a* gene and the *VA RNA* gene in a forward direction (clockwise direction, 5'→3') were collectively named pHNG (pHNG2, pHNG5 (including pHNG5K), pHNG8, pHNG9, etc.) and constructs prepared by inserting in a reverse direction (counterclockwise direction, 3'→5') were collectively named pHNGR (pHNGR8, etc.). Their cleavage maps are shown in FIGS. 5A and 5B.

[268]

[269]

Example 4. Preparation of AAV construct plasmid including transgene

[270]

An AAV construct plasmid including a transgene was prepared according to the method described in Korean Patent Application No. 10-2020-0084038. Specifically, the plasmid was prepared from a pUC57 plasmid, with AAV2 ITR (inverted terminal repeat) base sequences necessary for AAV capsid packaging on both sides and a CMV enhancer, a chicken β-actin promoter, a hybrid intron, an *eGFP* gene as a transgene, a WPRE sequence, four repeating miR142-3p target sequences and the pA sequence of bovine growth hormone included therebetween.

[271]

[272]

Example 5. Base sequencing

[273]

The base sequences of all the constructs prepared above were confirmed through base sequencing (DNA sequencing) (Bionics, Korea).

[274]

[275]

Example 6. Cell culture

[276]

HEK293 cells were wet-cultured using an MEM medium (Gibco, USA, Cat. No. 42360-032) containing 10% FBS (fetal bovine serum, Gibco, USA, Cat. No. 16000-044) and 1% penicillin-streptomycin (Gibco, USA, Cat. No. 15140-163) under

the condition of 5% CO₂ and 37 °C. Expi293 cells were wet-cultured using an Expi293 medium (Gibco, USA, Cat. No. A14351-01) supplemented with 1% penicillin-streptomycin under the condition of 8% CO₂ and 37 °C while shaking at 250 rpm.

[277]

[278] **Example 7. Transfection**

[279] **Example 7-1. Transfection of adhesion cells for production of AAV**

[280] For transfection, HEK293 cells were washed twice using DPBS (Gibco, USA, Cat. No. 14190-250), detached from the culture dish by treating with trypsin-EDTA (Gibco, USA, Cat. No. 25200-114), and then inoculated onto a 150-mm culture dish at 2x10⁷ cell/dish. After culturing for 24 hours, a pHelper-NG plasmid, a pUC-R2C2, pUC-R2C8 or pUC-R2C9 plasmid and an AAV construct plasmid including the transgene, 3.73 pmol each, were dissolved in 500 µL of Opti-MEM (Gibco, USA, Cat. No. 51985-034) for triple transfection. For double transfection, a pHION8 plasmid and an AAV construct plasmid including the transgene, 3.73 pmol each, were dissolved in 500 µL of Opti-MEM (Gibco, USA, Cat. No. 51985-034). Then, after diluting polyethylenimine (PEI, Polyscience, USA, Cat. No. 23966-1) corresponding to 2-fold of the total DNAs in 500 µL of Opti-MEM, the two solutions were mixed immediately to prepare a transfection solution. After incubating at room temperature for 30 minutes, 1 mL of the transfection solution was added to the culture dish on which the HEK293 cells were being cultured.

[281]

[282] **Example 7-2. Transfection of suspension cells for production of AAV**

[283] For production of AAV, 6x10⁸ cells were inoculated to 220 mL of an Expi293 medium in a 1-L Erlenmeyer culture flask. After culturing for about 3-4 hours for stabilization, a pHelper-NG plasmid, a pUC-R2C2, pUC-R2C5, pUC-R2C8 or pUC-R2C9 plasmid and an AAV construct plasmid including the transgene, 3.73 pmol each, were dissolved in 10 mL of Opti-MEM (Gibco, USA, Cat. No. 51985-034) for triple transfection. For double transfection, a pHION8 plasmid, a pHNG2 plasmid or a pHNG9 plasmid and an AAV construct plasmid including the transgene, 3.73 pmol each, were dissolved in 10 mL of Opti-MEM (Gibco, USA, Cat. No. 51985-034). Then, after diluting polyethylenimine (PEI, Polyscience, USA, Cat. No. 23966-1) corresponding to 2-fold of the total DNAs in 10 mL of Opti-MEM, the two solutions were mixed immediately to prepare a transfection solution. After incubating at room temperature for 30 minutes, 20 mL of the transfection solution was added to the culture flask.

[284]

[285] **Example 8. Purification of AAV**

[286] After conducting transfection for 72 hours in Example 7-1 or 7-2, the cells were

incubated for 3 hours after adding NaCl to the culture dish and the culture flask to a concentration of 500 mM (salt shock). Then, after recovering all the culture and removing debris through centrifugation, centrifugation was performed using Centricon (Vivaspin 20, 100,000 MWCO PES, Sartorius, Germany) having a molecular weight cut-off pore size of 100 kDa at 4 °C and 4000 rpm until about 200 µL of a supernatant remained. Then, the supernatant containing a recombinant adeno-associated virus vector was recovered and used for experiment or stored at -80 °C.

[287]

[288] **Example 9. Determination of AAV titer**

[289] qPCR (Bio-Rad, USA, CFX96) was conducted to determine the titer of the AAV purified in Example 8. The AAV was treated with DNaseI at 37 °C for 1 hour using a DNaseI reaction buffer (New England Biolab, USA, M0303S). Then, after treating the DNaseI-treated sample with proteinase K (Invitrogen, USA, Cat. No. AM2548) at 55 °C for 30 minutes, the proteinase K was inactivated by incubating at 95 °C for 15 minutes. The prepared sample was used as a template for qPCR, the AAV construct plasmid (7.4×10^8 to 7.4×10^4 , 10-fold dilution) was used to obtain a standard curve, and a recombinant adeno-associated virus 2 reference standard stock (rAAV2-RSS, ATCC, USA, Cat. No. VR-1616) or a recombinant adeno-associated virus 8 reference standard stock (rAAV8-RSS, ATCC, USA, Cat. No. VR-1816) was used as a positive control group. For qPCR for determining the titer, 2xSsoAdvanced Universal Probe Supermix (Bio-Rad, USA, Cat. No. 172-5282) and bGH poly A sequence-specific primers/probe set (#026, #027 and #028) were used. The qPCR was repeated for 40 cycles of denaturation at 95 °C for 10 minutes, followed by 95 °C for 30 seconds and 60 °C for 1 minute. The Bio-Rad CFX Maestro 1.1 software (Bio-Rad, USA) was used for analysis of the standard curve and quantification.

[290]

[291] **Example 10. Transfection using adeno-associated virus vector *in vitro***

[292] For transfection of the adeno-associated virus vector, HEK293 cells were inoculated on a 24-well culture plate with 4×10^5 cells per well. 24 hours later, each well was treated with 5 µM MG132 (Sigma-Aldrich, USA, Cat. No. M7449) for 8 hours. The cells were treated with 2,500 MOI (multiplicity of infection) of AAV2, or with 10,000 MOI of AAV8 or AAV9, and then cultured for 72 hours.

[293]

[294] **Example 11. Measurement of expression level of eGFP gene through flow cytometry**

[295] The expression of eGFP was measured by flow cytometry (Beckman Coulter, USA, CytoFlex). After transfection for 72 hours, the cells were treated with DPBS and detached using trypsin. After centrifuging the cells at 1500 rpm for 5 minutes, the cells

were resuspended by adding 500 μ L of DPBS supplemented with 2% FBS. The single cell region was distinguished from the FSC vs SSC plot and the expression level of FL1-A (green) was measured. The result of flow cytometry was analyzed using the FlowJo software 10.5.3 (Becton Dickinson & Company, USA).

[296]

[297] **Example 12. Statistical analysis**

[298] All experiments were repeated 3 or more times. Comparison between two groups was performed by Student's t-test using the Prism software 8.1.1 (GraphPad Software, Inc., USA), and comparison of three or more groups was performed by one-way ANOVA and Tukey's multiple comparisons test. * indicates $p < 0.05$, ** indicates $p < 0.01$ and *** indicates $p < 0.001$.

[299]

[300] ***Experimental results***

[301] **1. Selection of Helper-In-One plasmid construct showing increased AAV8 production**

[302] **1-1. Effect of triple transfection and double transfection using pHION8 series on increased or decreased AAV8 production in adhesion cells (HEK293)**

[303] The effect of the location of the *rep2-cap8* gene in the five Helper-In-One plasmid constructs used for double transfection (pHION8 series; pHION8-BF, pHION8-BR, pHION8-NF, pHION8-NR and pHION8-AF) on AAV8 production in adhesion cells (HEK293) was tested. Different results in AAV8 production were observed depending on the location of the *rep2-cap8* gene for double transfection with respect to AAV8 production by triple transfection as 100%. The AAV8 production was increased to 244.3% when the pHION8-BF construct (pHNG8) was used and to 170.2% when the pHION8-BR construct (pHNGR8) was used. When the pHION8-NF construct was used, the production was increased to 126.0%, but the increase was not statistically significant ($p = 0.82$). In contrast, the AAV8 production was decreased when the pHION8-NR or pHION8-AF construct was used (62.4% ($p = 0.50$), 71.7% ($p = 0.77$)) (FIG. 6).

[304]

[305] **1-2. Effect of triple transfection and double transfection using pHION8 series on increased or decreased AAV8 production in suspension cells (Expi293)**

[306] The same experiment as 1-1 was tested for suspension cells (Expi293F). Similarly to the adhesion cells, the AAV8 production was increased statistically significantly to 177.1% ($p < 0.001$) when the pHION8-BF construct was used and to 173.1% ($p < 0.001$) when the pHION8-BR construct was used, for double transfection, as compared to triple transfection. However, when the pHION8-NF, pHION8-NR and pHION8-AF constructs were used, the production was decreased statistically significantly to 40.9%,

66.7% and 43.1%, respectively (FIG. 7).

[307] These results suggest that the AAV production may vary depending on the relative location and direction of the *rep2-cap8* gene in the dual helper plasmid. Hereinafter, the construct wherein the *rep2-cap* gene is present in a forward direction (BF) at the BamHI site in the pHION plasmid for double transfection is named pHNG, and the construct wherein it is present in a reverse direction (BR) is named pHNGR. The number that follows indicates the serotype of the adeno-associated virus from which the *cap* gene is derived (pHION8-BF = pHNG8, pHION8-BR = pHNGR8).

[308]

[309] **2. Increased AAV2 production in adhesion cells (HEK293) by triple transfection and double transfection using pHNG2**

[310] A pHNG2 construct was prepared by inserting the *rep2-cap2* gene fragment in a forward direction using the BamHI site present between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene in a pHelper-NG plasmid, and it was used for double transfection (FIG. 2).

[311] When AAV2 production was compared for triple transfection and double transfection using the pHNG2, the AAV2 production was increased significantly to 279.6% ($p < 0.001$) for the double transfection as compared to the triple transfection (FIG. 8). Similarly to the increased AAV8 production by double transfection using pHNG8, this result suggests that AAV2 production by double transfection can be increased by locating the *rep2-cap2* gene between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene.

[312]

[313] **3. Increased AAV9 production by double transfection using pHNG9 in adhesion cells (HEK293)**

[314] For double transfection, a pHNG9 construct was prepared by cloning the *rep2-cap9* gene fragment in a forward direction using the BamHI site present between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene (FIG. 3).

[315] As a result of comparing AAV9 production by triple transfection and double transfection using pHNG9, it was confirmed that the AAV9 production was significantly increased to 214.0% ($p < 0.001$) by the double transfection as compared to the triple transfection (FIG. 9). This result was consistent to the increased AAV8 or AAV2 production by double transfection using pHNG8 and pHNG2. In conclusion, this suggests that the production of adeno-associated virus serotype 9 (AAV9) by double transfection can also be increased by locating the *rep2-cap* gene between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene.

[316]

[317] **4. Increased AAV5 production by double transfection using pHNG5K in adhesion cells (HEK293)**

[318] For double transfection, a pHNG5K construct was prepared by cloning the *rep2-cap5* gene fragment in a forward direction using the BamHI site present between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene (FIG. 4).

[319] As a result of comparing AAV5 production by triple transfection and double transfection using pHNG5K, it was confirmed that the AAV5 production was significantly increased to 194.7% ($p = 0.002$) by the double transfection as compared to the triple transfection (FIG. 10). This result was consistent to the increased AAV8, AAV2 or AAV9 production by double transfection using pHNG8, pHNG2 and pHNG9.

[320] In conclusion, this suggests that the production of adeno-associated virus serotype 5 (AAV5) by double transfection can also be increased by locating the *rep2-cap* gene between the beginning portion of the *E2a* gene and the ending portion of the *VA RNA* gene.

[321]

[322] **5. Equivalence of cell transduction efficiency of AAV8s produced by triple transfection or double transfection (pHNG8 or pHNGR8 construct)**

[323] The cellular infectivity and gene expression ability of AAV8 produced by triple transfection and AAV8 produced by double transfection using pHNG8 and pHNGR8 were compared. The AAV8s were designed to express the eGFP protein. After infecting HEK293 cells with 10,000 MOI of AAV8, the expression level of eGFP in the cells was measured by flow cytometry 72 hours later. As a result, when compared with the AAV8 produced by triple transfection, the AAV8 produced by double transfection using pHNG8 and pHNGR8 showed similar cellular infectivity (Triple: 6.0%, pHNG8: 5.4%, pHNGR8: 5.7%) and also showed similar eGFP expression level (pHNG8: 93.4%, pHNGR8: 94.6%) in the cells. This result suggests that the AAV8 produced by triple transfection and the AAV8 produced by double transfection using pHNG8 and pHNGR8 have no difference in cellular infectivity and gene expression ability after infection (FIG. 11).

[324]

[325] **6. Equivalence of transduction efficiency of AAV2s produced by triple transfection or double transfection (pHNG2)**

[326] In gene delivery (transduction) using AAV2, the cellular infectivity and gene expression ability of AAV2 produced by triple transfection and AAV2 produced by double transfection using pHNG2 were compared. The AAV2s were designed to express the eGFP protein. After infecting HEK293 cells with 2,500 MOI of AAV2, the

proportion of cells expressing eGFP and the expression level of eGFP in the cells were measured by flow cytometry 72 hours later. As a result, when compared with the AAV2 produced by triple transfection, the AAV2 produced by double transfection using pHNG2 showed at least comparable cellular infectivity (Triple: 32.0%, BF: 44.7%; $p = 0.38$) and also showed comparable or slightly higher eGFP expression level (129.6%, $p = 0.02$) per infected cell. This result suggests that the AAV2 produced by double transfection using pHNG2 exhibits cellular infectivity and gene expression ability after infection at least comparable to those of the AAV2 produced by triple transfection (FIG. 12).

[327]

[328] **7. Equivalence of transduction efficiency of AAV9s produced by triple transfection or double transfection (pHNG9)**

[329] In gene delivery (transduction) using AAV9, the cellular infectivity and gene expression ability of AAV9 produced by triple transfection and AAV9 produced by double transfection using pHNG9 were compared. The AAV9s were designed to express the eGFP protein. After infecting HEK293 cells with 10,000 MOI of AAV9, the expression level of eGFP in the cells was measured by flow cytometry 72 hours later. As a result, when compared with the AAV9 produced by triple transfection, the AAV9 produced by double transfection using pHNG9 showed similar eGFP expression level (90.9%, $p = 0.35$). This result suggests that the AAV9 produced by triple transfection and the AAV9 produced by double transfection using pHNG9 have no difference in cellular infectivity and gene expression ability (FIG. 13).

[330]

[331] Although the specific exemplary embodiments of the present disclosure have been described above, those having ordinary knowledge in the art will be able to variously change and modify the present disclosure without departing from the technical idea of the present disclosure described in the claims through addition, change, deletion, etc. of elements, and such changes and modifications also belong to the scope of the present disclosure.

Claims

- [Claim 1] A dual helper plasmid comprising an *E2a* gene, *E4* gene, *VA RNA* gene, and *rep-cap* gene, wherein the *E2a*, *E4*, and the *VA RNA* genes are linked sequentially, and wherein the *rep-cap* gene is located between the 5'-terminal of the *E2a* gene and the 3'-terminal of the *VA RNA* gene in a clockwise direction (from 5' to 3').
- [Claim 2] The dual helper plasmid of claim 1, wherein the 5'-terminal of the *rep-cap* gene is linked to the 5'-terminal of the *E2a* gene, and wherein the 3'-terminal of the *rep-cap* gene is linked to the 3'-terminal of the *VA RNA* gene.
- [Claim 3] A dual helper plasmid comprising an *E2a* gene, *E4* gene, *VA RNA* gene, and *rep-cap* gene, wherein the *E2a*, *E4*, and the *VA RNA* genes are linked sequentially, and wherein the *rep-cap* gene is located between the 5'-terminal of the *E2a* gene and the 3'-terminal of the *VA RNA* gene in a counterclockwise direction (from 3' to 5').
- [Claim 4] The dual helper plasmid of claim 3, wherein the 3'-terminal of the *rep-cap* gene is linked to the 5'-terminal of the *E2a* gene, and wherein the 5'-terminal of the *rep-cap* gene is linked to the 3'-terminal of the *VA RNA* gene.
- [Claim 5] The dual helper plasmid of any one of claims 1 to 4, wherein the *rep-cap* gene comprises a *rep* gene and a *cap* gene, and wherein the 3'-terminal of the *rep* gene is linked to the 5'-terminal of the *cap* gene.
- [Claim 6] The dual helper plasmid of any one of claims 1, 2, and 5, wherein the *E2a* gene, *E4* gene, *VA RNA* gene, and *rep-cap* gene are arranged as shown in the cleavage map of FIG. 5A.
- [Claim 7] The dual helper plasmid of any one of claims 3 to 5, wherein the *E2a* gene, *E4* gene, *VA RNA* gene, and *rep-cap* gene are arranged as shown in the cleavage map of FIG. 5B.
- [Claim 8] The dual helper plasmid of any one of claims 5 to 7, wherein the *rep* gene comprises a *rep2* gene derived from adeno-associated virus serotype 2 (AAV2).
- [Claim 9] The dual helper plasmid according to claim 8, wherein the *rep2* gene comprises the sequence set forth in SEQ ID NO 29.
- [Claim 10] The dual helper plasmid of any one of claims 5 to 9, wherein the *cap* gene comprises a *cap* gene derived from adeno-associated virus serotype 2 (AAV2; *cap2*), serotype 5 (AAV5; *cap5*), serotype 8 (AAV8; *cap8*), or serotype 9 (AAV9; *cap9*).


- [Claim 11] The dual helper plasmid according to claim 10, wherein the *cap* gene comprises the sequence set forth in SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, or SEQ ID NO 33.
- [Claim 12] The dual helper plasmid of any one of claims 1 to 11, wherein the *E2a* gene comprises an *E2a* gene derived from adenovirus serotype 5 (Ad5).
- [Claim 13] The dual helper plasmid of claim 12, wherein the *E2a* gene comprises the sequence set forth in SEQ ID NO 34.
- [Claim 14] The dual helper plasmid of any one of claims 1 to 13, wherein the *E4* gene comprises an *E4* gene derived from adenovirus serotype 5 (Ad5).
- [Claim 15] The dual helper plasmid of claim 14, wherein the *E4* gene comprises the sequence set forth in SEQ ID NO 35.
- [Claim 16] The dual helper plasmid of any one of claims 1 to 15, wherein the *VA RNA* gene comprises a *VA RNA* gene derived from adenovirus serotype 5 (Ad5).
- [Claim 17] The dual helper plasmid of claim 16, wherein the *VA RNA* gene comprises the sequence set forth in SEQ ID NO 36.
- [Claim 18] A dual helper plasmid comprising a regulatory component, wherein the regulatory component comprises (from 5' to 3'):
- (i) an *E2a* gene, which comprises the sequence set forth in SEQ ID NO: 34;
 - (ii) an *E4* gene, which comprises the sequence set forth in SEQ ID NO: 35;
 - (iii) a *VA RNA* gene, which comprises the sequence set forth in SEQ ID NO: 36;
 - (iv) a *cap* gene, which comprises the sequence set forth in SEQ ID NO: 30; and
 - (v) a *rep* gene, which comprises the sequence set forth in SEQ ID NO: 29.
- [Claim 19] A dual helper plasmid comprising a regulatory component, wherein the regulatory component comprises (from 5' to 3'):
- (i) an *E2a* gene, which comprises the sequence set forth in SEQ ID NO: 34;
 - (ii) an *E4* gene, which comprises the sequence set forth in SEQ ID NO: 35;
 - (iii) a *VA RNA* gene, which comprises the sequence set forth in SEQ ID NO: 36;
 - (iv) a *cap* gene, which comprises the sequence set forth in SEQ ID NO: 31; and

- (v) a *rep* gene, which comprises the sequence set forth in SEQ ID NO: 29.
- [Claim 20] A dual helper plasmid comprising a regulatory component, wherein the regulatory component comprises (from 5' to 3'):
- (i) an *E2a* gene, which comprises the sequence set forth in SEQ ID NO: 34;
 - (ii) an *E4* gene, which comprises the sequence set forth in SEQ ID NO: 35;
 - (iii) a *VA RNA* gene, which comprises the sequence set forth in SEQ ID NO: 36;
 - (iv) a *cap* gene, which comprises the sequence set forth in SEQ ID NO: 32; and
 - (v) a *rep* gene, which comprises the sequence set forth in SEQ ID NO: 29.
- [Claim 21] A dual helper plasmid comprising a regulatory component, wherein the regulatory component comprises (from 5' to 3'):
- (i) an *E2a* gene, which comprises the sequence set forth in SEQ ID NO: 34;
 - (ii) an *E4* gene, which comprises the sequence set forth in SEQ ID NO: 35;
 - (iii) a *VA RNA* gene, which comprises the sequence set forth in SEQ ID NO: 36;
 - (iv) a *cap* gene, which comprises the sequence set forth in SEQ ID NO: 33; and
 - (v) a *rep* gene, which comprises the sequence set forth in SEQ ID NO: 29.
- [Claim 22] The dual helper plasmid of any one of claims 18 to 21, wherein the *rep* gene and the *cap* gene are in a clockwise direction.
- [Claim 23] The dual helper plasmid of claim 22, wherein the 5'-terminal of the *rep* gene is linked to the 5'-terminal of the *E2a* gene, wherein the 3'-terminal of the *rep* gene is linked to the 5'-terminal of the *cap* gene, and wherein the 3'-terminal of the *cap* gene is linked to 3'-terminal of the *VA RNA* gene.
- [Claim 24] The dual helper plasmid of any one of claims 18 to 21, wherein the *rep* gene and the *cap* gene are in a counterclockwise direction.
- [Claim 25] The dual helper plasmid of claim 24, wherein the 5'-terminal of the *rep* gene is linked to the 3'-terminal of the *VA RNA* gene, wherein the 3'-terminal of the *rep* gene is linked to the 5'-terminal of the *cap* gene,


- and wherein the 3'-terminal of the *cap* gene is linked to the 5'-terminal of the *E2a* gene.
- [Claim 26] The dual helper plasmid of any one of claims 1 to 25, which further comprises an antibiotic resistance gene.
- [Claim 27] The dual helper plasmid of claim 26, wherein the antibiotic resistance gene comprises an ampicillin resistance gene, a kanamycin resistance gene, or both.
- [Claim 28] The dual helper plasmid of claim 27, wherein the ampicillin resistance gene comprises the sequence set forth in SEQ ID NO: 37.
- [Claim 29] The dual helper plasmid of claim 27, wherein the kanamycin resistance gene comprises the sequence set forth in SEQ ID NO: 38.
- [Claim 30] A composition comprising the dual helper plasmid of any one of claims 1 to 27.
- [Claim 31] The composition of claim 30, which further comprises an additional plasmid.
- [Claim 32] The composition of claim 31, wherein the additional plasmid is an AAV construct plasmid.
- [Claim 33] The composition of claim 31, wherein the additional plasmid comprises:
(a) an inverted terminal repeat (ITR);
(b) a transgene; and
(c) a control element operably linked to the transgene.
- [Claim 34] The composition of claim 33, wherein the control element comprises a promoter, enhancer, exon sequence, intron sequence, splicing donor or acceptor sequence, miRNA target sequence, woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) sequence, polyadenylation (pA) sequence, or combinations thereof.
- [Claim 35] The composition of any one of claims 30 to 34, wherein the transgene encodes a wild type polypeptide or any variant thereof, a fusion protein, an antibody or an antigen-binding fragment thereof, a RNA-based molecule, or any combination thereof.
- [Claim 36] A cell comprising the dual helper plasmid of any one of claims 1 to 29, or the composition of any one of claims 30 to 35.
- [Claim 37] A method of producing a recombinant AAV, comprising modifying a cell to comprise a first plasmid and a second plasmid, wherein the first plasmid is the dual helper plasmid of any one of claims 1 to 29, and wherein the second plasmid comprises a transgene.
- [Claim 38] The method of claim 37, wherein the modifying comprises transfecting

- the cell with the first plasmid and the second plasmid.
- [Claim 39] The method of claim 37 or 38, further comprising isolating the produced recombinant AAV.
- [Claim 40] A method of increasing the yield of recombinant AAV during production, comprising modifying a cell to comprise a first plasmid and a second plasmid, wherein the first plasmid is the dual helper plasmid of any one of claims 1 to 29 and the second plasmid comprises a transgene, and wherein the amount of recombinant AAV produced after the modifying is increased compared to the corresponding amount produced with a reference method.
- [Claim 41] The method of claim 40, wherein the reference method comprises modifying a corresponding cell to comprise the following three separate plasmids: i) a Rep-Cap plasmid comprising a gene encoding Rep protein and Cap protein; ii) a helper plasmid comprising a gene encoding the proteins (E2a, E4) and VA RNAs of adenovirus; and iii) an AAV construct plasmid comprising a transgene.
- [Claim 42] The method of claim 40 or 41, wherein the amount of recombinant AAV produced is increased by at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, or at least about 50-fold, as compared to the corresponding amount produced using the reference method.
- [Claim 43] A recombinant AAV produced by the method of any one of claims 40 to 62.
- [Claim 44] A pharmaceutical formulation comprising the recombinant AAV of claim 43, and a pharmaceutically acceptable excipient.
- [Claim 45] A method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject the recombinant AAV of claim 43 or the pharmaceutical formulation of claim 44.
- [Claim 46] The recombinant AAV of claim 43 or the pharmaceutical formulation of claim 44 for treating a disease or disorder in a subject in need thereof.
- [Claim 47] Use of the recombinant AAV of claim 43 or the pharmaceutical formulation of claim 44 in the manufacture of a medicament for treating a disease or disorder in a subject in need thereof.


[Fig. 1A]




[Fig. 1B]




[Fig. 1C]




[Fig. 1D]




[Fig. 1E]




[Fig. 1F]




[Fig. 2]




[Fig. 3]




[Fig. 4]




[Fig. 5A]




[Fig. 5B]




[Fig. 6]




[Fig. 7]




[Fig. 8]




[Fig. 9]




[Fig. 10]




[Fig. 11]



[Fig. 12]



[Fig. 13]



<110> Neuracle Genetics Inc.

<120> Novel Dual Helper Plasmid

<130> PCT852

<150> KR 10-2021-0068364

<151> 2021-05-27

<150> US 17/750,241

<151> 2022-05-20

<160> 38

<170> KoPatentIn 3.0

<210> 1

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligo ID NO: 001

<400> 1

tgaacaataa atgatttaaa tcaggtatgg ctgccgatgg ttatcttcca g 51

<210> 2

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligo ID NO: 002

<400> 2

taacaagcaa ttacagatta cgggtgaggt aacggg 36

<210> 3

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligo ID NO: 003

<400> 3

taatctgtaa ttgcttgta atcaataaac cgtttaattc gtttcag 47

<210> 4

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligo ID NO: 004

<400> 4
tttaaactcat ttattgttca aagatgcagt catccaaatc cac 43

<210> 5
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 005

<400> 5
attaactaca agctgtttcc tgtgtgaaat tgttatcc 38

<210> 6
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 006

<400> 6
gcggctgcgc ttaagccagc cccgacacc 29

<210> 7
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 007

<400> 7
tgaacaataa atgatttaa tcaggtatgg ctgccg 36

<210> 8
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 008

<400> 8
ggaaacagct tgtagttaat gattaacccg ccatgc 36

<210> 9
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 009

<400> 9
gctggcttaa gcgagccgc catg 24

<210> 10
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 010

<400> 10
taacaagcaa ttacagatta cgagtcaggt atctgg 36

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 011

<400> 11
ggtcgctggg gaccttaatc 20

<210> 12
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 012

<400> 12
ccatggctac gtagataagt agcatg 26

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 013

<400> 13
gattaaggtc cccagcgacc 20

<210> 14
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 014

<400> 14
acttatctac gtagccatgg aaactagata agaaagaaat acg 43

<210> 15
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 015

<400> 15
taacaagcaa ttacagatta cgagtcaggt atctggtgc 39

<210> 16
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 016

<400> 16
ggaagatctt taagcgcagc cgccatg 27

<210> 17
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 017

<400> 17
ggaagatctt gtagttaatg attaaccgc catgc 35

<210> 18
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 018

<400> 18
ggcacttttc ggggaaatgt g 21

<210> 19
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 019

<400> 19
caatctaaag tatatatgag taaacttggt ctgacag 37

<210> 20
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 020

<400> 20
atgataccct tgcgaattta tccacc 26

<210> 21
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 021

<400> 21
cacatttccc cgaaaagtgc c 21

<210> 22
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 022

<400> 22
ggtggataaa ttcgcaaggg tatcat 26

<210> 23
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 023

<400> 23
acctatcaca tctttttcca aaactgc 27

<210> 24
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligo ID NO: 024

<400> 24
 gcagttttgg aaaaagatgt gataggt 27

<210> 25
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligo ID NO: 025

<400> 25
 ctgtcagacc aagtttactc atatatactt tagattg 37

<210> 26
 <211> 16
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligo ID NO: 026

<400> 26
 gccagccatc tgttgt 16

<210> 27
 <211> 16
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligo ID NO: 027

<400> 27
 ggagtggcac cttcca 16

<210> 28
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligo ID NO: 028

<400> 28
 tccccgtgc cttccttgac c 21

<210> 29
 <211> 1866
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> rep2 gene

<400> 29

atgccgggggt tttacgagat tgtgattaag gtccccagcg accttgacga gcatctgccc 60
ggcattttctg acagctttgt gaactgggtg gccgagaagg aatgggagtt gccgccagat 120
tctgacatgg atctgaatct gattgagcag gcaccctga ccgtggccga gaagctgcag 180
cgcgactttc tgacggaatg gcgccgtgtg agtaaggccc cggaggcctt tttctttgtg 240
caatttgaga agggagagag ctacttcac atgcacgtgc tcgtggaaac caccggggtg 300
aatccatgg ttttgggacg tttcctgagt cagattcgcg aaaaactgat tcagagaatt 360
taccgcggga tcgagccgac tttgccaaac tggttcgcgg tcacaaagac cagaaatggc 420
gccggaggcg ggaacaaggt ggtggatgag tgctacatcc ccaattactt gctcccaaa 480
accagcctg agctccagtg ggcgtggact aatatggaac agtatttaag cgctgtttg 540
aatctcacgg agcgtaaacg gttggtggcg cagcatctga cgcacgtgtc gcagacgcag 600
gagcagaaca aagagaatca gaatcccaat tctgatgcgc cggatgatcag atcaaaaact 660
tcagccaggt acatggagct ggtcgggtgg ctcgtggaca aggggattac ctcggagaag 720
cagtggatcc aggaggacca ggcctcatal atctccttca atgcggcctc caactcgcgg 780
tcccaaatca aggctgcctt ggacaatcgc ggaaagatta tgagcctgac taaaaccgcc 840
cccgactacc tgggtgggcca gcagcccgtg gaggacattt ccagcaatcg gatttataaa 900
atthttggaac taaacgggta cgatcccaa tatgcggctt ccgtctttct gggatgggcc 960
acgaaaaagt tcggcaagag gaacaccatc tggctgtttg ggcctgcaac taccgggaag 1020
accaacatcg cggaggccat agcccacact gtgcccttct acgggtgcgt aaactggacc 1080
aatgagaact ttcccttcaa cgactgtgtc gacaagatgg tgatctggtg ggaggagggg 1140
aagatgaccg ccaaggtcgt ggagtcggcc aaagcattc tcggaggaag caaggtgcgc 1200
gtggaccaga aatgcaagtc ctcggcccag atagaccga ctcccgtgat cgtcacctcc 1260
aacaccaaca tgtgcgccgt gattgacggg aactcaacga cttcgaaca ccagcagccg 1320
ttgcaagacc ggatgttcaa atthgaaact acccgccgtc tggatcatga ctttgggaag 1380
gtcaccaagc aggaagtcaa agactttttc cgggtgggcaa aggatcacgt ggttgaggtg 1440
gagcatgaat tctacgtcaa aaagggtgga gccaaagaaa gaccgcccc cagtgcgca 1500
gatataagtg agcccaaacg ggtgcgcgag tcagttgcgc agccatcgac gtcagacgcg 1560
gaagcttcga tcaactacgc agacaggtac caaaacaaat gttctcgtca cgtgggcatg 1620
aatctgatgc tgthttccctg cagacaatgc gagagaatga atcagaattc aaatatctgc 1680
ttcactcacg gacagaaaga ctgthttagag tgctthcccg tgcagaatc tcaaccctt 1740
tctgtcgtca aaaaggcgtg tcagaaactg tgctacattc atcatatcat gggaaagggtg 1800
ccagacgctt gcactgcctg cgatctggtc aatgtggatt tggatgactg catctthgaa 1860
caataa 1866

<210> 30
<211> 2208
<212> DNA
<213> Artificial Sequence

<220>
<223> cap2 gene

<400> 30
atggctgccg atggttatct tccagattgg ctgaggaca ctctcttga aggaataaga 60
cagtgggtgga agctcaaacc tggcccacca ccaccaaagc ccgagagcg gcataaggac 120
gacagcaggg gtcttgtgct tcctgggtac aagtacctcg gacccttcaa cggactcgac 180
aaggagagc cggatcaacga ggcagacgcc gcggccctcg agcacgaca agcctacgac 240
cggcagctcg acagcggaga caacccttac ctcaagtaca accacgccga cgcggagttt 300
caggagcgc ttaaagaaga tacgtctttt gggggcaacc tcggagagc agtcttccag 360
gcgaaaaaga gggttcttga acctctgggc ctggttgagg aacctgttaa gacggctccg 420
ggaaaaaaga ggccggtaga gcactctcct gtggagccag actcctctc gggaaccgga 480
aaggcgggcc agcagcctgc aagaaaaaga ttgaattttg gtcagactgg agacgcagac 540
tcagtacctg acccccagcc tctcggacag ccaccagcag cccctctgg tctgggaact 600
aatacgatgg ctacaggcag tggcgcacca atggcagaca ataacgaggg cgccgacgga 660
gtgggtaatt cctcgggaaa ttggcattgc gattccacat ggatgggca cagagtcac 720
accaccagca cccgaacctg ggccctgccc acctacaaca accacctta caaacaatt 780
tccagccaat caggagcctc gaacgacaat cactactttg gctacagcac cccttggggg 840
tattttgact tcaacagatt ccaactgccac tttcaccac gtgactggca aagactcatc 900
aacaacaact ggggattccg acccaagaga ctcaacttca agctctttaa cattcaagtc 960
aaagaggatca cgcagaatga cggtagcagc acgattgcca ataaccttac cagcacggtt 1020
cagggtgttta ctgactcggga gtaccagctc ccgtacgtcc tcggctcggc gcatcaagga 1080
tgctcccgc cgttcccagc agacgtcttc atggtgccac agtatggata cctcacctg 1140
aacaacggga gtcaggcagt aggacgtctc tcattttact gcctggagta ctttccttct 1200
cagatgctgc gtaccgaaa caactttacc ttcagctaca cttttgagga cgttcctttc 1260
cacagcagct acgctcacag ccagagtctg gaccgtctca tgaatcctct catcgaccag 1320
tacctgtatt acttgagcag acaaacact ccaagtggaa ccaccacgca gtcaaggctt 1380
cagttttctc aggccggagc gactgacatt cgggaccagt ctaggaactg gcttcctgga 1440
ccctgttacc gccagcagcg agtatcaaag acatctgagg ataacaaca cagtgaatac 1500
tcgtggactg gagctaccaa gtaccacctc aatggcagag actctctggt gaatccgggc 1560
ccggccatgg caagccaca ggacgatgaa gaaaagtttt ttcctcagag cggggttctc 1620

atctttggga agcaaggctc agagaaaaca aatgtggaca ttgaaaaggt catgattaca	1680
gacgaagagg aaatcaggac aaccaatccc gtggctacgg agcagtatgg ttctgtatct	1740
accaacctcc agagaggcaa cagacaagca gctaccgcag atgtcaacac acaaggcgtt	1800
cttccaggca tggctcggca ggacagagat gtgtacctc aggggcccac ctgggcaaag	1860
attccacaca cggacggaca ttttcacccc tctcccctca tgggtggatt cggacttaaa	1920
caccctcctc cacagattct catcaagaac accccggtag ctgcgaatcc ttcgaccacc	1980
ttcagtgagg caaagtttgc ttccttcac acacagtact ccacgggaca ggtcagcgtg	2040
gagatcgagt gggagctgca gaaggaaac agcaaacgct ggaatcccga aattcagtac	2100
acttccaact acaacaagtc tgtaaatgtg gactttactg tggacactaa tggcgtgtat	2160
tcagagcctc gccccattgg caccagatac ctgactcgta atctgtaa	2208

<210> 31
 <211> 2175
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> cap5 gene

<400> 31	
atgtcttttg ttgatcacc tccagattgg ttggaagaag ttggtgaagg tcttcgcgag	60
tttttgggcc ttgaagcggg cccaccgaaa ccaaaacca atcagcagca tcaagatcaa	120
gcccgtggtc ttgtgctgcc tggttataac tatctcggac ccggaaacgg tctcgcgagc	180
ggagagcctg tcaacagggc agacgaggtc gcgcgagagc acgacatctc gtacaacgag	240
cagcttgagg cgggagacaa cccctacctc aagtacaacc acgcggagcgc cgagtttcag	300
gagaagctcg ccgacgacac atccttcggg ggaaacctcg gaaaggcagt ctttcaggcc	360
aagaaaaggg ttctcgaacc ttttggcctg gttgaagagg gtgctaagac ggcccctacc	420
ggaaagcggg tagacgacca ctttcaaaa agaaagaagg ctcggaccga agaggactcc	480
aagccttcca cctcgtcaga cgccgaagct ggaccagcg gatcccagca gctgcaaadc	540
ccagcccaac cagcctcaag tttgggagct gatacaatgt ctgcgggagg tggcggccca	600
ttgggcgaca ataaccaagg tgccgatgga gtgggcaatg cctcgggaga ttggcattgc	660
gattccacgt ggtgggggga cagagtcgtc accaagtcca cccgaacctg ggtgctgccc	720
agctacaaca accaccagta ccgagagatc aaaagcggct ccgtcgacgg aagcaacgcc	780
aacgcctact ttggatacag cccccctgg gggacttttg actttaaccg cttccacagc	840
cactggagcc cccgagactg gcaaagactc atcaacaact actggggcct cagaccccgg	900
tccctcagag tcaaaatctt caacattcaa gtcaaagagg tcacgggtgca ggactccacc	960
accaccatcg ccaacaacct cacctccacc gtccaagtgt ttacggacga cgactaccag	1020

ctgccctacg tcgtcggcaa cgggaccgag ggatgcctgc cggccttccc tccgcaggtc	1080
tttacgctgc cgagctacgg ttacgcgacg ctgaaccgcg acaacacaga aaatcccacc	1140
gagaggagca gctttcttctg cctagagtac tttcccagca agatgctgag aacgggcaac	1200
aactttgagt ttacctacaa ctttgaggag gtgcccttcc actccagctt cgctcccagt	1260
cagaacctgt tcaagctggc caaccgctg gtggaccagt acttgtaccg cttcgtgagc	1320
acaaataaca ctggcggagt ccagttcaac aagaacctgg ccgggagata cgccaacacc	1380
tacaaaaact ggttcccggg gcccatgggc cgaaccagg gctggaacct gggctccggg	1440
gtcaaccgcg ccagtgtcag cgccttcgcc acgaccaata ggatggagct cgagggcgcg	1500
agttaccagg tgccccgca gccgaacggc atgaccaaca acctccaggg cagcaacacc	1560
tatgccttgg agaacactat gatcttcaac agccagccgg cgaaccggg caccaccgcc	1620
acgtacctcg agggcaacat gctcatcacc agcgagagcg agacgcagcc ggtgaaccgc	1680
gtggcgtaca acgtcggcgg gcagatggcc accaacaacc agagctccac cactgcccc	1740
gcgaccggca cgtacaacct ccaggaaatc gtgcccggca gcgtgtggat ggagaggac	1800
gtgtacctcc aaggacctat ctgggccaag atcccagaga cggggcgca ctttcacccc	1860
tctccggcca tgggaggatt cggactcaaa caccaccgc ccatgatgct catcaagaac	1920
acgcctgtgc ccggaaatat caccagcttc tcggacgtgc ccgtcagcag cttcatcacc	1980
cagtacagca ccgggcaggt caccgtggag atggagtggg agctcaagaa ggaaaactcc	2040
aagaggtgga acccagagat ccagtacaca aacaactaca acgaccccc gtttgtggac	2100
tttgccccgg acagcaccgg ggaatacaga accaccagac ctatcggaac ccgatacctt	2160
accgacccc tttaa	2175

<210> 32
 <211> 2217
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> cap8 gene

<400> 32	
atggctgccg atggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc	60
gagtgggtggg cgctgaaacc tggagccccg aagcccaaag ccaaccagca aaagcaggac	120
gacggccggg gtctgggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac	180
aaggggggagc ccgtcaacgc ggcggacgca gcggccctcg agcacgacaa ggcttacgac	240
cagcagctgc aggcgggtga caatccgtac ctgcggtata accacgccga cgccgagttt	300
caggagcgtc tgcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag	360
gccaagaagc gggttctcga acctctcggt ctggttgagg aaggcgctaa gacggctcct	420

ggaaagaaga gaccggtaga gccatcacc cagcgttctc cagactcctc tacgggcatc	480
ggcaagaaag gccaacagcc cgccagaaaa agactcaatt ttggtcagac tggcgactca	540
gagtcagttc cagaccctca acctctcggg gaacctccag cagcgcctc tgggtgtggga	600
cctaatacaa tggctgcagg cgggtggcgca ccaatggcag acaataacga aggcgccgac	660
ggagtgggta gttcctcggg aaattggcat tgcgattcca catggctggg cgacagagtc	720
atcaccacca gcacccgaac ctgggccctg cccacctaca acaaccacct ctacaagcaa	780
atctccaacg ggacatcggg aggagccacc aacgacaaca cctacttcgg ctacagcacc	840
ccctgggggt attttgactt taacagattc cactgccact tttcaccacg tgactggcag	900
cgactcatca acaacaactg gggattccgg cccaagagac tcagcttcaa gctcttcaac	960
atccagggtca aggaggctac gcagaatgaa ggcaccaaga ccatcgccaa taacctcacc	1020
agcaccatcc aggtgtttac ggactcggag taccagctgc cgtacgttct cggctctgcc	1080
caccagggct gcctgcctcc gttcccggcg gacgtgttca tgattccca gtacggctac	1140
ctaactca acaacggtag tcaggccgtg ggacgctcct cttctactg cctggaatac	1200
tttccttcgc agatgctgag aaccggcaac aacttcaggt ttacttacac cttcgaggac	1260
gtgcctttcc acagcagcta cgcccacagc cagagcttg accggctgat gaatcctctg	1320
attgaccagt acctgtacta cttgtctcgg actcaaaaa caggaggcac ggcaaatacg	1380
cagactctgg gcttcagcca aggtgggcct aatacaatgg ccaatcaggc aaagaactgg	1440
ctgccaggac cctgttaccg ccaacaacgc gtctcaacga caaccgggca aaacaacaat	1500
agcaactttg cctggactgc tgggacaaaa taccatctga atggaagaaa ttcattggct	1560
aatcctggca tcgctatggc aacacacaaa gacgacgagg agcgtttttt tcccagtaac	1620
gggatcctga tttttgcaa aaaaaatgct gccagagaca atgcggatta cagcgatgtc	1680
atgctcacca gcgaggaaga aatcaaaacc actaacctg tggctacaga ggaatacgg	1740
atcgtggcag ataacttgca gcagcaaac acggctcctc aaattggaac tgtcaacagc	1800
cagggggcct taccgggtat ggtctggcag aaccgggacg tgtacctgca ggggtccatc	1860
tgggccaaga ttctcacac ggacggcaac ttccaccgt ctccgctgat gggcggcttt	1920
ggcctgaaac atcctccgcc tcagatcctg atcaagaaca cgcctgtacc tgcggatcct	1980
ccgaccacct tcaaccagtc aaagctgaac tctttcatca cgcaatacag caccggacag	2040
gtcagcgtgg aaattgaatg ggagctgcag aaggaaaaca gcaagcgtg gaaccccgag	2100
atccagtaca cctccaacta ctacaaatct acaagtgtgg actttgctgt taatacagaa	2160
ggcgtgtact ctgaaccccg cccattggc acccgttacc tcaccgtaa tctgtaa	2217

<210> 33
 <211> 2211
 <212> DNA
 <213> Artificial Sequence

<220>

<223> cap9 gene

<400> 33

atggctgccg atggttatct tccagattgg ctcgaggaca accttagtga aggaattcgc 60
gagtgggtggg ctttgaaac tggagcccct caaccaagg caaatcaaca acatcaagac 120
aacgctcgag gtcttgtgct tccgggttac aaataccttg gaccggcaa cggactcgac 180
aagggggagc cggtaacgc agcagacgcg gcggccctcg agcacgaaa ggcttacgac 240
cagcagctca aggccggaga caaccgtac ctcaagtaca accacgccga cgccgagttc 300
caggagcggc tcaaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttcag 360
gccaaaaaga ggcttcttga acctcttggc ctggttgagg aagcggctaa gacggctcct 420
ggaaagaaga ggcttcttga acctcttggc ctggttgagg aagcggctaa gacggctcct 480
aaatcgggtg cacagcccgc taaaaagaga ctcaatttcg gtcagactgg cgacacagag 540
tcagtcccag accctcaacc aatcgagaa cctccgcag cccctcagg tgtgggatct 600
cttacaatgg cttcaggtgg tggcgacca gtggcagaca ataacgaagg tgccgatgga 660
gtgggtagtt cctcgggaaa ttggcattgc gattccaat ggctggggga cagagtcac 720
accaccagca cccgaacctg ggccctgccc acctacaaca atcacctcta caagcaatc 780
tccaacagca catctggagg atcttcaaat gacaacgcct acttcggcta cagcaccccc 840
tgggggtatt ttgacttcaa cagattccac tgccacttct caccacgtga ctggcagcga 900
ctcatcaaca acaactgggg attccggcct aagcgactca acttcaagct cttcaacatt 960
caggtcaaag aggttacgga caacaatgga gtcaagacca tcgcaataa ccttaccagc 1020
acggtccagg tcttcacgga ctcagactat cagctcccgt acgtgctcgg gtcggctcac 1080
gagggctgcc tcccgccgtt cccagcggac gttttcatga ttcctcagta cgggtatctg 1140
acgcttaatg atggaagcca ggccgtgggt cgttcgtcct tttactgcct ggaatatttc 1200
ccgtcgaaa tgctaagaac gggtacaac ttccagtca gctacgagtt tgagaacgta 1260
cctttcata gcagctacgc tcacagcaa agcctggacc gactaatgaa tccactcatc 1320
gaccaatact tgtactatct ctcaaagact attaacggtt ctggacagaa tcaacaacg 1380
ctaaaattca gtgtggccgg acccagcaac atggctgtcc agggaaagaaa ctacatacct 1440
ggaccagct accgacaaca acgtgtctca accactgtga ctcaaaaca caacagcgaa 1500
tttgcttggc ctggagcttc ttcttgggct ctcaatggac gtaatagctt gatgaatcct 1560
ggacctgcta tggccagcca caaagaagga gaggaccgtt tctttccttt gtctggatct 1620
ttaatTTTTG gcaacaagg aactggaaga gacaacgtgg atcgggaaa agtcatgata 1680
accaacgaag aagaaattaa aactactaac ccggtagcaa cggagtccta tggacaagtg 1740
gccacaaacc accagagtgc ccaagcacag gcgcagaccg gctgggttca aaaccaagga 1800

atacttccgg gtatggtttg gcaggacaga gatgtgtacc tgcaaggacc catttgggcc 1860
 aaaattcctc acacggacgg caactttcac ctttctccgc tgatgggagg gtttgaatg 1920
 aagcaccgcg ctctcagat cctcatcaaa aacacacctg tacctgcgga tcctccaacg 1980
 gccttcaaca aggacaagct gaactctttc atcaccagct attctactgg ccaagtcagc 2040
 gtggagatcg agtgggagct gcagaaggaa aacagcaagc gctggaaccg ggagatccag 2100
 tacacttcca actattacaa gtctaataat gttgaatttg ctgttaatac tgaaggtgta 2160
 tatagtgaac cccgccccat tggcaccaga tacctgactc gtaatctgta a 2211

<210> 34
 <211> 5340
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> E2a gene

<400> 34
 cgaccgcacc ctgtgacgaa agccgcccgc aagctgcgcc cctgagttag tcatctgaac 60
 ttcggcctgg gcgtctctgg gaagtaccac agtggtgagg gcgggacttt cctggtacac 120
 cagggcagcg ggccaactac ggggattaag gttattacga ggtgtggtgg taatagccgc 180
 ctgttccaag agaattcggg ttcggtgggc gcggattccg ttgaccggg atatcatgtg 240
 gggccccgcg ctcatgtagt ttattcgggt tgagtagtct tgggcagctc cagccgcaag 300
 tcccatttgt ggctggtaac tccacatgta gggcgtggga atttccttgc tcataatggc 360
 gctgacgaca ggtgctggcg ccgggtgtgg ccgctggaga tgacgtagtt ttcgcgctta 420
 aatttgagaa agggcgcgaa actagtcctt aagagtcagc gcgcagtatt tactgaagag 480
 agcctccgcg tcttccagcg tgcgccgaag ctgatcttcg cttttgtgat acaggcagct 540
 gcgggtgagg gatcgcagag acctgttttt tattttcagc tcttgttctt ggcccctgct 600
 ctgttgaaat atagcataca gagtgggaaa aatcctgttt ctaagctcgc gggtcgatac 660
 gggttcgttg ggcgccagac gcagcgtcc tcctcctgct gctgccgccg ctgtggattt 720
 cttgggcttt gtcagagtct tgctatccgg tcgcctttgc ttctgtgtgg ccgctgctgt 780
 tgctgccgct gccgctgccg ccggtgcagt atgggctgta gagatgacgg tagtaatgca 840
 ggatgttacg ggggaaggcc acgccgtgat ggtagagaag aaagcggcgg gcgaaggaga 900
 tgttgcccc acagtcttgc aagcaagcaa ctatggcggt cttgtgcccg cgccatgagc 960
 ggtagccttg gcgctgttgt tgctcttggg ctaacggcgg cggctgcttg gacttaccgg 1020
 ccctggttcc agtgggtgcc catctacggt tgggtcggcg aacgggcagt gccggcggcg 1080
 cctgaggagc ggaggttgta gccatgctgg aaccggttgc cgatttcttg ggcgccggcg 1140
 aggggaatgc gaccgagggt gacggtgttt cgtctgacac ctcttcgacc tcggaagctt 1200

cctcgtctag gctctccag tcttccatca tgtcctcctc ctctcgtcc aaaacctcct	1260
ctgcctgact gtcccagtat tcctcctcgt ccgtgggtgg cggcggcagc tgcagcttct	1320
ttttgggtgc catcctggga agcaagggcc cgcggctgct gctgataggg ctgcggcggc	1380
ggggggattg ggttgagctc ctgcgggac tgggggtcca agtaaaccct ccgtcccttt	1440
cgtagcagaa actcctggcg ggctttgttg atggcttgca attggccaag aatgtggccc	1500
tgggtaatga cgcaggcggg aagctccgca tttggcgggc gggattggtc ttcgtagaac	1560
ctaactctctg gggcgtggta gtcctcaggt acaaatttgc gaaggtaacg cgacgtccac	1620
agccccggag tgagtttcaa ccccggagcc gcggactttt cgtcaggcga gggaccctgc	1680
agctcaaagg taccgataat ttgactttcg ttaagcagct gcgaattgca aaccaggagg	1740
cgggtcgggg tgcataggtt gcagcgacag tgacactcca gtagaccgtc accgctcacg	1800
tcttccatta tgtcagagtg gtaggcaagg tagttggcta gctgcagaag gtagcagtgg	1860
cccaaagcg gcggagggca ttcgcggtac ttaatgggca caaagtcgct aggaagtgca	1920
cagcaggtgg cgggcaagat tcctgagcgc tctaggataa agttcctaaa gttctgcaac	1980
atgctttgac tggatgaagtc tggcagaccc tgttgcaggg ttttaagcag gcgttcgggg	2040
aaaatgatgt ccgccagggt cgcggccacg gagcgcctct tgaaggcctg ccataggtcc	2100
ttcaagtttt gcttttagcag tttctgcagc tccttgaggt tgcaactctc caagcactgc	2160
tgccaaacgc ccatggccgt ctgccagggt tagcatagaa ataagtaaac gcagtcgcgg	2220
acgtagtctc ggcgcgcctc gcccttgagc gtggaatgaa gcacgttttg cccaaggcgg	2280
ttttcgtgca aaattccaag gtaggagacc aggttgacaga gctccacgtt ggagatcttg	2340
caggcctggc gtacgtagcc ctgtcgaag gtgtagtgca atgtttcctc tagcttgccg	2400
tgcatctccg ggtcagcaaa gaaccgctgc atgcaactca gctccacggt aacgagcact	2460
gcggccatca ttagtttgcg tcgctcctcc aagtcggcag gctcgcgctg ttgaagccag	2520
cgcgctagct gctcgtcgc aactgcgggt aggcctcct ctgtttgttc ttgcaaattt	2580
gcatccctct ccaggggctg cgcacggcgc acgatcagct cactcatgac tgtgctcatg	2640
accttggggg gtaggttaag tgccgggtag gcaaagtggg tgacctgat gctgcgtttt	2700
agtacggcta ggcgcgcgtt gtcaccctcg agttccacca aactccaga gtgactttca	2760
ttttcgtgt tttcctgttg cagagcgttt gccgcgcgt tctcgtcgcg tccaagacc	2820
tcaaagattt ttggcacttc gttgagcgag gcgatatcag gtatgacagc gccctgccgc	2880
aaggccagct gcttgtccgc tcggctgcgg ttggcacggc aggatagggg tatcttgacg	2940
ttttggaaaa agatgtgata ggtggcaagc acctctggca cggcaaatac ggggtagaag	3000
ttgaggcgcg ggttgggctc gcatgtgccg ttttctggc gtttgggggg tacgcgcggt	3060
gagaataggt ggcgttcgta ggcaaggctg acatccgcta tggcgagggg cacatcgctg	3120

cgctcttgca acgcgtcgca gataatggcg cactggcgct gcagatgctt caacagcacg	3180
tcgtctccca catctaggta gtcgccatgc ctttcgtccc cccgcccgac ttgttcctcg	3240
tttgctctg cgttgtcctg gtcttgcttt ttatcctctg ttggtactga gcggtcctcg	3300
tcgtcttcgc ttacaaaacc tgggtcctgc tcgataatca cttcctcctc ctcaagcggg	3360
ggcgcctcga cggggaaggt ggtaggcgcg ttggcggcat cggaggaggc ggtggtggcg	3420
aactcagagg gggcggttag gctgtccttc ttctcgactg actccatgat ctttttctgc	3480
ctataggaga aggaaatggc cagtcgggaa gaggagcagc gcgaaaccac ccccgagcgc	3540
ggacgcggtg cggcgcgacg tcccccaacc atggaggacg tgtcgtcccc gtccccgtcg	3600
ccgccgcctc cccgggcgcc cccaaaaaag cggatgaggc ggcgtatcga gtccgaggac	3660
gaggaagact catcacaaga cgcgctgggtg ccgcgcacac ccagcccgcg gccatcgacc	3720
tcggcggcgg atttggccat tgcgcccagg aagaaaaaga agcgccttc tccaagccc	3780
gagcgcggcg catcaccaga ggtaatcgtg gacagcgagg aagaaagaga agatgtggcg	3840
ctacaaatgg tgggtttcag caaccaccg gtgctaataca agcatggcaa aggaggtaag	3900
cgcacagtgc ggcggctgaa tgaagacgac ccagtggcgc gtggtatgcg gacgcaagag	3960
gaagaggaag agcccagcga agcggaaagt gaaattacgg tgatgaacc gctgagtgtg	4020
ccgatcgtgt ctgctggga gaaggcatg gaggctgcbc gcgctgat ggacaagtac	4080
cacgtggata acgatctaaa ggcgaacttc aaactactgc ctgaccaagt ggaagctctg	4140
gcggccgtat gcaagacctg gctgaacgag gagcaccgcb ggttcagct gaccttcacc	4200
agcaacaaga cttttgtgac gatgatgggg cgattcctgc aggcgtacct gcagtcgttt	4260
gcagaggtga cctacaagca tcacgagccc acgggctgcb cgttgtggct gcaccgctgc	4320
gctgagatcg aaggcgagct taagtgtcta cacggaagca ttatgataaa taaggagcac	4380
gtgattgaaa tggatgtgac gagcgaaaac gggcagcgcg cgctgaagga gcagtctagc	4440
aaggccaaga tcgtgaagaa ccggtggggc cgaaatgtgg tgcagatctc caacaccgac	4500
gcaaggtgct gcgtgcacga cgcggcctgt ccggccaatc agttttccgg caagtcttgc	4560
ggcatgttct tctctgaagg cgcaaaggct cagggtggctt ttaagcagat caaggctttt	4620
atgcaggcgc tgtatcctaa cgcccagacc gggcacggtc accttttgat gccactacgg	4680
tgcgagtgca actcaaagcc tgggcacgcb ccctttttgg gaaggcagct accaaagttg	4740
actccgttcg ccctgagcaa cgcggaggac ctggacgcbg atctgatctc cgacaagagc	4800
gtgctggcca gcgtgcacca cccggcgtg atagtgttcc agtgctgcaa ccctgtgtat	4860
cgcaactcgc gcgcbgagg cggaggcccc aactgcgact tcaagatatc ggcgcccgac	4920
ctgctaaacg cgttggtgat ggtgcbgac ctgtggagtg aaaacttcac cgagctgccg	4980
cggatggttg tcctgagtt taagtggagc actaaacacc agtatcgcaa cgtgtccctg	5040
ccagtggcgc atagcgatgc gcggcagaac ccctttgatt tttaaaccgc gcagacggca	5100

agggtggggg taaataatca cccgagagtg taaaataaa agcatttgcc tttattgaaa	5160
gtgtctctag tacattatntt ttacatgttt ttcaagtac aaaaagaagt ggcgctccta	5220
atctgcgcac tgtggctgcg gaagtagggc gaggggcct ccaggaagct gtagagctgt	5280
tcctggttgc gacgcagggt gggctgtacc tggggactgt tgagcatgga gttgggtacc	5340
	5340

<210> 35
 <211> 3037
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> E4 gene

<400> 35	
gttttagggc ggagtaactt gtatgtgttg ggaattgtag ttttctaaa atgggaagtt	60
acgtaacgtg ggaaaacgga agtgacgatt tgaggaagtt gtgggttttt tggctttcgt	120
ttctgggcgt aggttcgctg gcggttttct ggggtttttt tgtggacttt aaccgttacg	180
tcatttttta gtcctatata tactcgcctc gcacttggcc cttttttaca ctgtgactga	240
ttgagctggt gccgtgtcga gtgggttttt tttaataggt tttctttttt actggttaagg	300
ctgactgtta tggctgccgc tgtggaagcg ctgtatgttg ttctggagcg ggaggggtgct	360
attttgccta ggcaggaggg tttttcaggt gtttatgtgt ttttctctcc tattaatntt	420
gttatacctc ctatgggggc tgtaatgttg tctctacgcc tgcgggatag tattcccccg	480
ggctatnttcg gtcgcttttt agcactgacc gatgtgaatc aacctgatgt gtttaccgag	540
tcttacatta tgactccgga catgaccgag gagctgtcgg tgggtccttt taatcacggt	600
gaccagtttt tttacggtca cgccggcatg gccgtagtcc gtcttatgct tataagggtt	660
gtttttcctg ttgtaagaca ggcttctaata gtttaaatgt ttttttgta tttatntttg	720
tgtttatgca gaaaccgca gacatgtttg agagaaaaat ggtgtccttt tctgtggtgg	780
ttccggagct tacctgcctt tatctgcatg agcatgacta cgatgtgctt tcttttttgc	840
gcgaggcttt gcctgatttt ttgagcagca ccttgcatntt tatacgcgg cccatgcaac	900
aagcttacat cggggctacg ctggtttagca tagctccgag tatgctgtgc ataatacagt	960
tgggttcttt tgtcatggtt cctggcgggg aagtggccgc gctggctcgt gcagacctgc	1020
acgattatgt tcagctggcc ctgcgaaggg acctacggga tcgcggtatt tttgttaatg	1080
ttccgctttt gaatcttata caggctctgtg aggaacctga atttttgcaa tcatgattcg	1140
ctgcttgagg ctgaaggtgg agggcgctct ggagcagatt tttacaatgg ccggacttaa	1200
tattcgggat ttgcttagag atatattgag aaggtggcga gatgagaatt atttgggcat	1260
ggttgaaggt gctggaatgt ttatagagga gattcacctt gaagggttta gcctttacgt	1320

ccacttggac	gtgagggccg	tttgcctttt	ggaagccatt	gtgcaacatc	ttacaaatgc	1380
cattatctgt	tctttggctg	tagagtttga	ccacgccacc	ggaggggagc	gcgttcactt	1440
aatagatcct	cattttgagg	ttttggataa	tcttttggaa	taaaaaaaaa	aacatggttc	1500
ttccagctct	tcccgctcct	cccgtgtgtg	actcgcagaa	cgaatgtgta	ggttggctgg	1560
gtgtggctta	ttctgcggtg	gtggatgtta	tcagggcagc	ggcgcataaa	ggagtttaca	1620
tagaaccgga	agccaggggg	cgcttgatg	ctttgagaga	gtggatatac	tacaactact	1680
acacagagcg	atctaagcgg	cgagaccgga	gacgcagatc	tgtttgtcac	gcccgcacct	1740
ggttttgctt	caggaaatat	gactacgtcc	ggcgttccat	ttggcatgac	actacgacca	1800
acacgatctc	ggttgtctcg	gcgcactccg	tacagtaggg	atcgtctacc	tccttttgag	1860
acagaaacc	gcgctaccat	actggaggat	catccgctgc	tgcccgaatg	taacactttg	1920
acaatgcaca	acgtgagtta	cgtgcgaggt	cttccctgca	gtgtgggatt	tacgctgatt	1980
caggaatggg	ttgttccctg	ggatatggtt	ctaacgcggg	aggagcttgt	aatcctgagg	2040
aagtgtatgc	acgtgtgcct	gtgttgtgcc	aacattgata	tcatgacgag	catgatgatc	2100
catggttacg	agtcctgggc	tctccactgt	cattgttcca	gtcccggttc	cctgcagtgt	2160
atagccggcg	ggcaggtttt	ggccagctgg	tttaggatgg	tggtggatgg	cgccatgttt	2220
aatcagaggt	ttatatggta	ccgggaggtg	gtgaattaca	acatgccaaa	agaggaatg	2280
tttatgtcca	gcgtgtttat	gaggggtcgc	cacttaatct	acctgcgctt	gtggtatgat	2340
ggccacgtgg	gttctgtggt	ccccgccatg	agctttggat	acagcgcctt	gactgtggg	2400
attttgaaca	atattgtggt	gctgtgctgc	agttactgtg	ctgatttaag	tgagatcagg	2460
gtgcgctgct	gtgcccggag	gacaaggcgc	cttatgctgc	gggcggtgcg	aatcatcgct	2520
gaggagacca	ctgccatggt	gtattcctgc	aggacggagc	ggcggcggca	gcagtttatt	2580
cgcgcgctgc	tgacgacca	ccgccctatc	ctgatgcacg	attatgactc	tacccccatg	2640
taggcgtgga	cttctccttc	gccgccggtt	aagcaaccgc	aagtggaca	gcagcctgtg	2700
gctcagcagc	tggacagcga	catgaactta	agtgagctgc	ccggggagtt	tattaatatc	2760
actgatgagc	gtttggctcg	acaggaaacc	gtgtggaata	taacacctaa	gaatatgtct	2820
gttaccatg	atatgatgct	ttttaaggcc	agccggggag	aaaggactgt	gtactctgtg	2880
tgttgggagg	gaggtggcag	gttgaatact	agggttctgt	gagtttgatt	aaggtacggt	2940
gatctgtata	agctatgtgg	tggtggggct	atactactga	atgaaaaatg	acttgaat	3000
ttctgcaatt	gaaaaataaa	cacgttgaaa	cataaca			3037

<210> 36
 <211> 731
 <212> DNA
 <213> Artificial Sequence

<220>

<223> VA RNAs gene

<400> 36

atccgtagat gtacctggac atccaggtga tgccggcggc ggtggtggag gcgcgcggaa 60
agtcgcggac gcggttccag atgttgcgca gcggcaaaaa gtgctccatg gtcgggacgc 120
tctggccggt caggcgcgcg caatcgttga cgctctagac cgtgcaaaag gagagcctgt 180
aagcaagcac tcttccgtgg tctggtggat aaattcgcaa gggatcatg gcggacgacc 240
ggggttcgag ccccgatatcc ggccgtccgc cgtgatccat gcggttaccg cccgcgtgtc 300
gaacccaggt gtgcgacgtc agacaacggg ggagtgtcc ttttggcttc cttccaggcg 360
cggcggctgc tgcgctagct tttttggcca ctggccgcgc gcagcgtaaag cggttaggct 420
ggaaaagcga agcattaagt ggctcgtcc ctgtagccgg agggttattt tccaagggtt 480
gagtcgcggg acccccgtt cgagtctcgg accggccgga ctgcggcgaa cgggggtttg 540
cctccccgtc atgcaagacc ccgcttgcaa attcctccgg aacaggacgac gagccccttt 600
tttgcttttc ccagatgcat ccggtgctgc ggcagatgcg cccccctct cagcagcggc 660
aagagcaaga gcagcggcag acatgcaggg caccctcccc tcctcctacc gcgtcaggag 720
gggcgacatc c 731

<210> 37

<211> 861

<212> DNA

<213> Artificial Sequence

<220>

<223> Ampicillin Resistance Gene

<400> 37

atgagtattc aacatttccg tgtcggcctt attccctttt ttgcggcatt ttgccttct 60
gtttttgctc acccagaaac gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca 120
cgagtgggtt acatcgaact ggatctcaac agcggtaaga tccttgagag ttttcgcccc 180
gaagaacggt ttccaatgat gagcactttt aaagttctgc tatgtggcgc ggtattatcc 240
cgtattgacg ccgggcaaga gcaactcggc cgccgcatac actattctca gaatgacttg 300
gttgagtact caccagtcac agaaaagcat cttacggatg gcatgacagt aagagaatta 360
tgcagtgctg ccataacatc gactgataac actgcggcca acttacttct gacaacgatc 420
ggaggaccga aggagctaac cgcttttttg cacaacatgg gggatcatgt aactcgcctt 480
gatcgttggg aaccggagct gaatgaagcc ataccaaagc acgagcgtga caccacgatg 540
cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg gcgaactact tactctagct 600
tcccggcaac aattaataga ctggatggag gcggataaag ttgcaggacc acttctgcgc 660
tcggcccttc cggctggctg gtttattgct gataaatctg gagccggtga gcgtgggtct 720

cgcggtatca ttgcagcact ggggccagat ggtaagccct cccgtatcgt agttatctac 780
acgacgggga gtcaggcaac tatggatgaa cgaaatagac agatcgctga gataggtgcc 840
tactgatta agcattggta a 861

<210> 38
<211> 798
<212> DNA
<213> Artificial Sequence

<220>
<223> Kanamycin Resistance Gene

<400> 38
atgattgaac aggatggcct gcatgcgggt agcccggcag cgtgggtgga acgtctgttt 60
ggctatgatt gggcgagca gaccattggc tgctctgatg cggcgggtgtt tcgtctgagc 120
gcgagggtc gtccgggtgct gtttgtgaaa accgatctga gcggtgcgct gaacgagctg 180
caggatgaag cggcgctct gagctggctg gccaccaccg gtgttccgtg tgcggcgggtg 240
ctggatgtgg tgaccgaagc gggccctgat tggctgctgc tgggcgaagt gccgggtcag 300
gatctgctgt ctagccatct ggcgccggca gaaaaagtga gcattatggc ggatgccatg 360
cgtcgtctgc ataccctgga cccggcgacc tgtccgtttg atcatcaggc gaaacatcgt 420
attgaacgtg cgcgtaccg tatggaagcg ggcctgggtg atcaggatga tctggatgaa 480
gaacatcagg gcctggcacc ggcagagctg tttgcgcgtc tgaaagcgag catgccggat 540
ggcgaagatc tggtggtgac ccatgggtgat gcgtgcctgc cgaacattat ggtggaaaat 600
ggccgtttta gcggctttat tgattgcggc cgtctgggcg tggcggatcg ttatcaggat 660
attgcgctgg ccaccctga tattgcggaa gaactgggcg gcgaatgggc ggatcgtttt 720
ctgggtgctgt atggcattgc ggcaccggat agccagcgta ttgcgtttta tcgtctgctg 780
gatgaatttt tctaataa 798